WO2014033597A1 - 5-azaindole compounds with anticancer and antiangiogenic activities - Google Patents
5-azaindole compounds with anticancer and antiangiogenic activities Download PDFInfo
- Publication number
- WO2014033597A1 WO2014033597A1 PCT/IB2013/056809 IB2013056809W WO2014033597A1 WO 2014033597 A1 WO2014033597 A1 WO 2014033597A1 IB 2013056809 W IB2013056809 W IB 2013056809W WO 2014033597 A1 WO2014033597 A1 WO 2014033597A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- formula
- use according
- tubulin
- groups
- Prior art date
Links
- SRSKXJVMVSSSHB-UHFFFAOYSA-N 1h-pyrrolo[3,2-c]pyridine Chemical class N1=CC=C2NC=CC2=C1 SRSKXJVMVSSSHB-UHFFFAOYSA-N 0.000 title abstract description 19
- 230000001772 anti-angiogenic effect Effects 0.000 title description 9
- 230000003217 anti-cancerogenic effect Effects 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 135
- 210000004027 cell Anatomy 0.000 claims abstract description 105
- 102000029749 Microtubule Human genes 0.000 claims abstract description 74
- 108091022875 Microtubule Proteins 0.000 claims abstract description 74
- 210000004688 microtubule Anatomy 0.000 claims abstract description 69
- 239000003814 drug Substances 0.000 claims abstract description 31
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 30
- 238000011282 treatment Methods 0.000 claims abstract description 30
- 229940079593 drug Drugs 0.000 claims abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 208000035475 disorder Diseases 0.000 claims abstract description 10
- 230000002265 prevention Effects 0.000 claims abstract description 10
- 230000022131 cell cycle Effects 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 6
- 208000030852 Parasitic disease Diseases 0.000 claims abstract description 6
- 230000033115 angiogenesis Effects 0.000 claims abstract description 6
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 6
- 238000011160 research Methods 0.000 claims abstract description 5
- 241001631646 Papillomaviridae Species 0.000 claims abstract description 4
- 239000003619 algicide Substances 0.000 claims abstract description 4
- 230000002363 herbicidal effect Effects 0.000 claims abstract description 4
- 239000004009 herbicide Substances 0.000 claims abstract description 4
- 208000031888 Mycoses Diseases 0.000 claims abstract description 3
- -1 nitro, amino Chemical group 0.000 claims description 21
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000003282 alkyl amino group Chemical group 0.000 claims description 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 4
- 244000045947 parasite Species 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 3
- XNVMFDGFXSZPDU-UHFFFAOYSA-N cyano nitroformate Chemical compound [O-][N+](=O)C(=O)OC#N XNVMFDGFXSZPDU-UHFFFAOYSA-N 0.000 claims description 3
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 241000224482 Apicomplexa Species 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010012646 Diabetic blindness Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 201000005485 Toxoplasmosis Diseases 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 210000004081 cilia Anatomy 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 210000003495 flagella Anatomy 0.000 claims 1
- 102000004243 Tubulin Human genes 0.000 description 73
- 108090000704 Tubulin Proteins 0.000 description 73
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 63
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- 230000000694 effects Effects 0.000 description 34
- 229960001338 colchicine Drugs 0.000 description 31
- 238000000034 method Methods 0.000 description 26
- 238000003556 assay Methods 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 19
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 19
- 230000027455 binding Effects 0.000 description 18
- 239000000243 solution Substances 0.000 description 16
- 239000000872 buffer Substances 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 239000005090 green fluorescent protein Substances 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 13
- 239000002609 medium Substances 0.000 description 12
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 12
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 11
- 229960003048 vinblastine Drugs 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 230000029115 microtubule polymerization Effects 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 229930012538 Paclitaxel Natural products 0.000 description 8
- 210000002257 embryonic structure Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 229960001592 paclitaxel Drugs 0.000 description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229940123237 Taxane Drugs 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 238000010166 immunofluorescence Methods 0.000 description 7
- 230000008880 microtubule cytoskeleton organization Effects 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 238000005556 structure-activity relationship Methods 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 229920002554 vinyl polymer Polymers 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 229940122803 Vinca alkaloid Drugs 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 235000013601 eggs Nutrition 0.000 description 5
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 230000036515 potency Effects 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 5
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000011278 mitosis Effects 0.000 description 4
- 230000000394 mitotic effect Effects 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 208000036878 aneuploidy Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000000423 cell based assay Methods 0.000 description 3
- 230000025084 cell cycle arrest Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 210000003837 chick embryo Anatomy 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000000512 collagen gel Substances 0.000 description 3
- 230000001085 cytostatic effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229950006344 nocodazole Drugs 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
- 229960004528 vincristine Drugs 0.000 description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 3
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 229920000298 Cellophane Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000004668 G2/M phase Effects 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100021339 Multidrug resistance-associated protein 1 Human genes 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 239000007990 PIPES buffer Substances 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 102000007432 Tubulin-tyrosine ligase Human genes 0.000 description 2
- 108020005542 Tubulin-tyrosine ligase Proteins 0.000 description 2
- 241000863480 Vinca Species 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 231100001075 aneuploidy Toxicity 0.000 description 2
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 208000036815 beta tubulin Diseases 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000004814 combretastatins Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000003278 egg shell Anatomy 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000010185 immunofluorescence analysis Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000025090 microtubule depolymerization Effects 0.000 description 2
- 108010066052 multidrug resistance-associated protein 1 Proteins 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000002135 phase contrast microscopy Methods 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 208000037965 uterine sarcoma Diseases 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- HONKEGXLWUDTCF-YFKPBYRVSA-N (2s)-2-amino-2-methyl-4-phosphonobutanoic acid Chemical compound OC(=O)[C@](N)(C)CCP(O)(O)=O HONKEGXLWUDTCF-YFKPBYRVSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- FPWIBJOGIQYKCJ-UHFFFAOYSA-N 1-(benzenesulfonyl)-4-chloroindole Chemical compound C1=CC=2C(Cl)=CC=CC=2N1S(=O)(=O)C1=CC=CC=C1 FPWIBJOGIQYKCJ-UHFFFAOYSA-N 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- AJKVQEKCUACUMD-UHFFFAOYSA-N 2-Acetylpyridine Chemical compound CC(=O)C1=CC=CC=N1 AJKVQEKCUACUMD-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- LYTMVABTDYMBQK-UHFFFAOYSA-N 2-benzothiophene Chemical compound C1=CC=CC2=CSC=C21 LYTMVABTDYMBQK-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- XYOUIHIDEFBMRU-UHFFFAOYSA-N 4-methoxy-2-[1-(4-methoxyphenyl)ethenyl]-1-methylpyrrolo[3,2-c]pyridine Chemical compound C1=CC(OC)=CC=C1C(=C)C1=CC2=C(OC)N=CC=C2N1C XYOUIHIDEFBMRU-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102100028624 Cytoskeleton-associated protein 5 Human genes 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 238000010867 Hoechst staining Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000766864 Homo sapiens Cytoskeleton-associated protein 5 Proteins 0.000 description 1
- 101001010835 Homo sapiens Intraflagellar transport protein 74 homolog Proteins 0.000 description 1
- 101000616438 Homo sapiens Microtubule-associated protein 4 Proteins 0.000 description 1
- 101000852716 Homo sapiens T-cell immunomodulatory protein Proteins 0.000 description 1
- 101000763890 Homo sapiens TIP41-like protein Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100029997 Intraflagellar transport protein 74 homolog Human genes 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- 101710134369 Kinesin-like protein KIF2C Proteins 0.000 description 1
- 102100023424 Kinesin-like protein KIF2C Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 102100021794 Microtubule-associated protein 4 Human genes 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000005465 Stathmin Human genes 0.000 description 1
- 108050003387 Stathmin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 101000926072 Varicella-zoster virus (strain Dumas) Envelope glycoprotein C Proteins 0.000 description 1
- 101000766862 Xenopus laevis Cytoskeleton-associated protein 5-A Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000015916 branching morphogenesis of a tube Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002275 effect on microtubule Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000009764 endothelial cell sprouting Effects 0.000 description 1
- 230000004076 epigenetic alteration Effects 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000003358 metastasis assay Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003550 mucous cell Anatomy 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000001962 taste-modifying agent Substances 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000010865 video microscopy Methods 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention relates to 5-azamdole type compounds of formula (1) for their use as drags, more particularly for the prevention and/or the treatment of diseases and/or disorders chosen amongst cancers; aagiogenesis related disorders; parasitic diseases; fungai diseases; autoimmune diseases; inflammatory diseases; warts such as warts caused by papilloma virus.
- the present invention also relates to pharmaceutical compositions comprising such compounds of formula (I).
- the use of at least one compound of formula (I) as research tool for the cell-cycle synchronization of microtubule drugs resistant cell lines is also part of the invention.
- the present invention concerns the use of at least one compound of formula (I) as an herbicide and/or an algaecide.
- Microtubules form, with the actin microfilaments and the intermediate filaments, the cytoskeleton of the eukaryotic cells. These are hollow tubular aggregates constituted of a single dimeric protein, i.e. the tubulin.
- the microtubule networks are in general nucleated at an organizing centre: the centrosome. These networks carry out multiple and vital roles such as organization of the cytoplasm, positioning of the organelles, cell motility and cell division.
- the microtubule network is reorganized to form the mitotic spindle, which is machinery used by cell to separate the duplicated chromosomes into two identical sets, before its cleavage into two daughter cells.
- Mitotic spindle integrity is controlled by specific checkpoints, Any undetected mitotic spindle dysfunction couid be at the origin of genomic instability and thus represents a potential source of tumorigenesis (Castillo et al, 2007; Kops et al, 2005).
- Microtubules assemble by polymerization of ⁇ / ⁇ dimers of tubulin. Microtubules are highly dynamic polymers able to rapidly polymerize from free tubulin dimers and to depolymerize just as rapidly. Microtubule dynamics are crucial to mitosis (Jordan and Wilson, 2004; Niethammer et al, 2007).
- the intrinsic microtubule dynamics is tightly regulated in the cell by interaction with an array of proteins that stabilize or destabilize microtubules, such as XMAP215 Disl/TOGp, MCAK, MAP4 and Opl8/stathmin (Holmfeldt et al, 2009; Kavallaris, 2010) or +TIPs (plus- end tracking proteins) such as EB1 (Akhmanova et al, 2005; Cottle et al, 2009; Small et al, 2003). Targeted perturbation of this finely tuned process constitutes a major therapeutic strategy ⁇ Honore et al, 2005).
- proteins that stabilize or destabilize microtubules such as XMAP215 Disl/TOGp, MCAK, MAP4 and Opl8/stathmin (Holmfeldt et al, 2009; Kavallaris, 2010) or +TIPs (plus- end tracking proteins) such as EB1 (Akhmanova et al, 2005
- Anti-mitotic drugs that interfere with the microtubule system are, indeed, key components of combination chemotherapies for the treatment of carcinomas (Kavallaris, 2010).
- Perturbation of microtubule dynamics by drugs constitutes one of the most powerful ways to suppress (at least transiently) tumor growth.
- most of these drugs have their therapeutic potential hampered by insufficient bioavailability and toxicity (myelosuppressi n, peripheral neurotoxicity).
- failure in cancer therapy is often related to the selection of tumor cells that have acquired resistance against microtubule binding drugs.
- many efforts are undertaken to identify new chemical entities that may overcome those resistance mechanisms (5-amino-2-aroylquinolines (Nien et al, 2010), 1,2,4-triazole (Arora et al, 2009), for example).
- anticancer drugs clinically important, including the Vinca alkaloids, vinblastine, vincristine, and vinorelbine and the taxanes paclitaxel and docetaxel specifically target tubulin and modify microtubules dynamics.
- tubulin is today one of the best validated targets in anticancer chemotherapy (Giannakakou et al, 2000; Jackson et al, 2007; Zhou and Giarmakakou, 2005).
- microtubule cytoskeleton in the etiology of a large number of diseases has been described, such as for example mental disorders (Andrieux et al, 2006; Andrieux et al, 2002; Begou et al, 2008) and neurodegenerative diseases (Denxtaut et al, 2005; Garcia et Cleveland, 2001), and viral (Ruthel et al, 2005), bacterial (Margalit et al, 2004) and parasitic (Morrissette and Sibley, 2002) infections.
- the pharmacological agents targeting the microtubule cytoskeleton and its various effectors may therefore exhibit a therapeutic advantage for the treatment of a large number of diseases (Lafanechere, 2008).
- the treatments used in anticancer chemotherapy target, in a favored manner, the dynamic behavior of the microtubules.
- it may be blocked by many agents that can bind to different sites of tubulin.
- Structural data concerning the binding of these different agents on tubulin have been obtained.
- Zinc-induced sheets of paclitaxel-stabilized tubulin proto filaments have been used for construction of a model of tubulin with bound paclitaxel. After fitting this model into electron density microtubule maps, the authors concluded that paclitaxel binds to ⁇ -tubulin facing the microtubule lumen (Snyder et al, 2001).
- Periwinkle alkaloids capable of depolymerizing the microtubules, have been identified as agents capable of arresting the cells in mitosis, with aberrant mitotic spindles. Subsequently, vincristine and vinblastine were introduced into clinical medicine in the 1960s and are still widely used in chemotherapy for testicular cancer, Hodgkin's disease or acute lymphoid leukemia,
- colchicine or combretastatm which inhibit the polymerization of the microtubules and also nocodazole.
- Taxanes and more particularly paclitaxel, interact specifically and reversibly with the microtubules with a stoichiometry of about one mole of taxane per one mole of tubulin. This interaction is accompanied by a stabilization of the microtubules.
- Paclitaxel and the other taxanes are differentiated from other anti-tubulin poisons mainly by the stabilizing effect that they exert on the microtubules.
- Cancer drugs such as paclitaxel or Vinca alkaloids were previously thought to work through opposite mechanisms.
- taxanes are extremely toxic since they also act on the microtubules of non-cancerous cells in proliferation (hematopoietic cells, mucous cells, etc.). Finally, they may adversely affect the peripheral neurons and give rise to significant side-effects.
- paclitaxel The therapeutic success of paclitaxel has maintained the advantage for the search for therapeutic agents that target tubulin.
- tubulin drugs are not surprising because tubulin is a major player not only in cell division but also in mitosis-independent cytoskeietal functions.
- the first subject of the present invention thus relates to 5-azaindole compounds of formula (I):
- the ring Ar is a C 4 -Ci 2 aryl or beteroary] ring, preferably a phenyl or pyridine ring, and more preferably a phenyl ring,
- - Rj H, optionally substituted Ci-C 6 alkyl, benzyl, arylsulfonyl, heteroarylsulfonyl, alkyloxycarbonyl or dialkylcarbamoyl groups, said substituents being independently selected from halogen, hydroxyl, cyano, nitro, carboxylate, carboxyester, ammo, Ci-C ⁇ alkyl, Ci-Q alkylamino, C 2 -C6 cycloamino or Ci-Q alkoxy groups,
- R5, R$ and R 7 identical or different, represent hydrogen or halogen atoms, hydroxyl, Ci-Ce alkyl, Ct-C 6 alkoxy, cyano, nitro, carboxylate, carboxyester, amino, Cj-Q alkylamino or C 2 -C ⁇ , cycloamino groups, and preferably R 3 ⁇ R s , R$ and R , identical or different, represent hydrogen atoms or Cj- e alkoxy groups,
- R H or an optionally substituted Ci-C 6 alkyl group
- the compounds of formula (I) of the invention were identified as compounds that disrupt microtubule array in a reversible manner. Reversibility rules out the possibility of covalent bond formation between tubulin and azaindoie derivatives. Since reversibility generally enables a better control of administrated compound dose during treatment, this characteristic is of importance for lead development. Biochemical experiments indicated that tubulin is an in vitro target of azaindoie derivatives and its polymerization inhibition is likely responsible for the observed phenotype. Complete microtubule depolymerization was observed in cells.
- Antiproliferative activities of the compounds of formula (I) revealed a broad spectrum of cytostatic effect with comparable efficiencies on cell lines with deficient p53 or overexpressing ⁇ ras, both generic or epi genetic alterations that are among the most common alterations found in cancer ceils.
- the 5 ⁇ azaindole compounds of formula (I) also exhibited antiproliferative activity in cell lines overexpressing the drug efflux pumps PgP, MRP1 and ABCG2, As the action of the compounds of formula (I) is reversible, these compounds may thus be used as research tool for cell synchronization experiments with resistant cells. Moreover, this property ma be exploited in the case of chemotherapeutic failure.
- the compounds of formula (I) also inhibit angiogenic sprouting from microvascular endothelial cell spheroids, which demonstrates that these compounds exert anti angiogenic activity in vivo on tumor cells.
- the standard assays for evaluating the performance of anticancer drugs involve human tumor xenografts in immunodeficient mice. Tumors grown on the chorioallantoic membrane (CAM) of chicken embryos constitute, however, a fast, easy and affordable system for a first preclinical analysis of the compound effects. The highly vascularized nature of the CAM greatly promotes the efficiency of tumor cell grafting.
- MDA-MB-231 tumor cells develop sizable tumors, but also they can escape the primary site, invade surrounding stroma, and reach distal portions of the CAM to form micro metastasis foci. Therefore, similar to some murine models, all steps of tumor growth and of the metastatic cascade are recapitulated in the chick embryo model but, importantly, in a very short period of time.
- the compounds of formula (I) are reversible microtubule depolymerizing agents that exert potent cytostatic effects on human cancer cells of diverse origins, including multidrug- resistant cells. Although they act in the micromolar range, their chemical structure is simpler than currently used microtubule polymerization inhibitors.
- the compounds of the invention also exhibit a significant inhibition of angiogenesis and tumor growth in chorioallantoid breast cancer xenografts.
- Alkyl groups are chosen among Cj.Ce alkyl groups such as methyl, ethyl, n- propyl, isopropyl, n-butyl, sec-butyl, tert-bxxtyl and isobutyl radicals;
- Alkoxy groups are chosen among Cj-Ce alkoxy groups such as methyloxy, ethyloxy, n-propyloxy, iso-propyloxy, n-butyloxy, sec-butyloxy, te ⁇ butyloxy and isobutyloxy radicals;
- Aryl group means any functional group or substituent derived from at least one simple aromatic ring; an aromatic ring corresponding to any planar cyclic compound having a delocalized ⁇ system in which each atom of the ring comprises a p-orbital, said p-orbitals overlapping themselves.
- aryl includes, but is not limited to, phenyl, biphenyl, 1 -naphthyl, 2-naphtyl, anthracyl, pyrenyl, and the substituted forms thereof.
- the aryl groups of the invention comprise preferably 4 to 12 carbon atoms, and more preferably 5 or 6 carbon atoms
- Heteroaryl group means any functional group or substituent derived from at least one aromatic ring as defined above and containing at least one heteroatom selected from P, S, O and N.
- heteroaryl includes, but is not limited to, furan, pyridine, pyrrole, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, tetrazole, pyridazole, pyridine, pyrazine, pyrimidine, pyridazine, benzofurane, isobenzofurane, indole, isomdole, ben20thiophene, benzo[c]thiophene i benzimidazole, indazole, benzoxazole, benzisoxazole, benzothiazole, quinoline, isoqumolme, qumoxaline, qumazoliue, cinnoline, purine
- Arylalkyl groups mean any group derived from an alkyl group as defined above wherein a hydrogen atom is replaced by an aryl as defined above;
- Heteroaryialkyl groups mean any group derived from an alkyl group as defined above wherein a hydrogen atom is replaced by a heteroaryl group as defined above;
- Alkylamino groups mean mono or di(CrC6)alkylamino group
- Cycloamino groups mean C 2 -C 6 cycloamino group such as aziridin-l-yl, azetidin-l-yl, pyrrolidm-l-yl, piperidm-l-yl, azepan-l-yl, tnorphoHn- -yi and thiomorpholin- -yI.
- halogen atoms are chosen among bromine, chlorine, fluorine and iodine, preferably bromine, chlorine and fluorine, and more preferably chlorine.
- pharmaceutically-acceptable refers to compounds, materials, compositions and/or dosage forms which are suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other complications commensurate with a reasonable benefit/risk ratio.
- Rj is an arylsulfonyl or a heteroarylsuifonyl group, preferably the aryl ring is a phenyl ring;
- Ri is an alkoxycarbonyl group, preferably i is the butoxycarbonyl
- Rj is a dialkylcarbamoyl group, preferably i is the dimethylcarbamoyl.
- R 5 CH 3 or a benzyl group.
- one of R j R 5 , R $ or R 7 is a Ci-Q alkoxy group when the others are hydrogen atoms.
- At least one of the R 3 , R 5 , 3 ⁇ 4 or R 7 radical is a OC3 ⁇ 4 group.
- Ar is a phenyl ring substituted by a OCH 3 group in position 4.
- the present invention relates more particularly to compounds of formula (1) for their use for the prevention and/or the treatment of diseases and/or disorders chosen amongst cancers; angiogenesis related disorders; parasitic disease; fungal disease; autoimmune diseases; inflammatory diseases; warts such as warts caused by papilloma virus.
- the present invention relates to compounds of formula (I) for their use for the prevention and/or treatment of;
- cancers chosen amongst testicular cancer, ovarian cancer s lung cancer, breast cancer, Hodgkin's disease, acute lymphoid leukemia, neuroblastoma, melanoma, glioma, glioblastoma, sarcoma, colon cancer, pancreatic cancer,
- angiogenesis related disorders chosen amongst diabetic blindness, macular degeneration, rheumatoid arthritis, psoriasis,
- autoimmune diseases chosen amongst multiple sclerosis, diabetic retinopathy, inflammatory diseases chosen amongst gout disease.
- the compounds of formula (I) may be prepared for example according to the method described in Nguyen et al, 1986.
- compositions comprising at least one compound of formula (I) according to the invention as an active principle, with at least one pharmaceutically-acceptable excipient or carrier, and with at least another active substance.
- pharmaceutically acceptable excipient refers to any diluents, adjuvants or vehicles, such as preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
- the pharmaceutical composition of the present invention may be administered by any suitable route, for example, by oral, buccal, inhalation, sublingual, nasal, percutaneous, i.e. transdermal or parenteral (including intravenous, intramuscular, subcutaneous and intracoronary) administration. Therefore, the pharmaceutical composition of the invention can be provided in various forms, such as in the form of hard gelatin capsules, of capsules, of compressed tablets, of suspensions to be taken orally, of lozenges or of injectable solutions, ointments, or in any other form appropriate to the method of administration.
- composition according to the invention includes those wherein a compound of formula (I) is administered in an effective amount to achieve its intended purpose. Determination of the effective amounts is well within the capability of those skilled in the art.
- a “therapeutically effective dose” refers to that amount of compound of formula (I) which results in achieving the desired effect.
- Toxicity and therapeutic efficacy of compound of formula (1) can be easily determined by standard pharmaceutical procedures in cell cultures or experimental animals, i.e, for determining the LJ1 ⁇ 2 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index, which is expressed as the ratio between LDso and ED 50 .
- the data obtained from such data can be used in formulating range of dosage for use in humans.
- the dosage of compound of formula (I) preferably lies within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed, and the route of administration.
- the exact formulation, route of administration, and dosage can be chosen by the individual physician in view of the patient's conditions. Dosage amount and interval of administration can be adjusted individually to provide plasma levels of compound of formula (1) which are sufficient to maintain the preventive or therapeutic effects.
- the amount of pharmaceutical composition administered will therefore depend on the subject being treated, on the subject's weight, the severity of the affliction and the manner of administration.
- the compounds of formula (I) can be administered alone, but they are preferably administered in admixture with at least one pharmaceutically acceptable carrier, the nature of which will depend on the intended route of administration and the presentation form...
- Pharmaceutical composition for use according to the present invention thus can be formulated in a conventional manner using one or more physiologically acceptable carriers comprising one or more excipient ⁇ s) and/or auxiliaries) that facilitate processing of the compounds of formula (I) into preparations which can be used pharmaceutically.
- excipients and auxiliaries which can be used in the pharmaceutical composition according to the invention, one can mention anti-agglomerating agents, preservatives agents, dyes, vitamins, inorganic salts, taste-modifying agents, smoothing agents, coating agents, isolating agents, stabilizing agents, wetting agents, anti- caking agents, dispersing agents, emulsifying agents, aromas, penetrating agents, solubilizing agents, etc., mixtures thereof and generally any excipient conventionally used in the pharmaceutical industry.
- the carrier when the pharmaceutical composition is administered orally, may comprise one or several excipients such as talc, lactose, starch or modified starches, cellulose or cellulose derivatives, polyethylene glycols, acrylic acid polymers, gelatin, magnesium stearate, animal or vegetal fats of natural or synthetic origin, paraffin derivatives, glycols, etc.
- excipients such as talc, lactose, starch or modified starches, cellulose or cellulose derivatives, polyethylene glycols, acrylic acid polymers, gelatin, magnesium stearate, animal or vegetal fats of natural or synthetic origin, paraffin derivatives, glycols, etc.
- compositions can be manufactured in a conventional manner, i.e. by conventional mixing, dissolving, granulating, dragee-making, emulsifying, encapsulating, entrapping or lyophilizing processes. Proper formulation is dependent upon the route of administration chosen.
- FIG. 1 shows the effect of two compounds of formula (I) according to the invention, CMOI and CM02, on microtubule network organization:
- B a-tubulin partition between soluble and insoluble fractions.
- HeLa cells were treated for 2 hours with 0.25% DMSO (vehicle control); 2 ⁇ colchicine and increasing concentrations of CMOI as indicated.
- Insoluble (I) and soluble (S) fractions were prepared as described in Materials and Methods. Equivalent volumes of extracts (20 ⁇ ,) were separated on 8% SDS-PAGE, and subjected to immunoblot analysis using monoclonal antibody specific for total a-tubulin. (C) same as (B), but with CM02.
- FIG. 2 shows the reversibility of CMOI and CM02 effects in HeLa cells.
- HeLa cells were treated for 2 hours with 0.25% DMSO (control); 5 ⁇ colchicine; 10 ⁇ nocodazole, 25 ⁇ nocodazole, 25 ⁇ CMOI or 25 ⁇ CM02, as indicated.
- Compounds were the removed removal and cells were incubated overnight in fresh medium. They were then fixed and stained for a-tubulin,
- FIG. 3 shows the effect of CMOI and CM02 on microtubule polymerization in vitro.
- MTP tubulin polymerization assay Tubulin was allowed to polymerize at 37°C, at the indicated conditions. Fluorescence of DAPI bound to microtubule was measured to monitor microtubule polymerization. Experiments were performed in triplicate, in the presence of increasing concentration of CMOI or CM02, as indicated. Results are presented as mean ⁇ standard error of the mean (SEM).
- FIG. 4 shows the effect of CMOI and CM02 on microtubule polymerization in vitro: Pure tubulin polymerization assay. Tubulin was allowed to polymerize at 37°C, at the indicated conditions. Fluorescence of DAPI bound to microtubule was measured to monitor microtubule polymerization. Experiments were performed in triplicate, in the presence of increasing concentration of CMOI or CM02, as indicated. Results are presented as mean ⁇ standard error of the mean (SEM).
- FIG. 5 represents the effect of CMOl and CM02 on the binding of [ 3 H] colchicine and f H] vinblastine to microtubule proteins.
- 50 nM [ 3 H] colchicine (black bars) or 30 nM [3 ⁇ 4] vinblastine (dashed bars) were competed with 100 ⁇ of CMOl, CM02, colchicine and vinblastine as described in Materials and Methods.
- Each value represents the mean ⁇ SEM from triplicate determinations.
- FIG. 6 represents the cell cycle distribution upon treatment of HeLa cells with CMOl and CM02.
- HeLa cells were incubated for 16 hours with DMSO (control), colchicine (2 ⁇ ), CMOl and CM02 (1 ⁇ and 25 ⁇ , as indicated).
- Cell cycle parameters were analyzed by flow cytometry, as described in Materials and Methods.
- the upper panel shows the graphs obtained for 1 and 25 ⁇ , as indicated, of CMOl and CM02 (black), compared with that obtained for DMSO (grey). Values (lower table) are expressed as percentage of the total cell population,
- FIG. 7 shows that the compounds of formula (I) inhibit capillary-like tube formation.
- FIG. 8 represents the quantitative analysis of endothelial sprouting in response to 5-azaindoles compounds of formula (I).
- FGF2 100 ng/ nL
- CMOl collagen- embedded HMEC-GFP spheroids
- CM02 CMOl
- CM02 CMOl
- CM02 CMOl
- CM02 CMOl
- CM02 CMOl
- CM02 CMOl
- CM02 ⁇ . ⁇ ⁇ to 25 ⁇ .
- the spheroids were observed under an epifluorescence microscope:
- A Overlay of phase contrast and fluorescence observations at the indicated concentrations of compounds.
- B Measure of the mean total sprout length of endothelial spheroids, performed by quantitative microscopy image analysis. In each condition, data represent the mean values ⁇ SE of multiple spheroids (n > 10) from one representative experiment out of two.
- CMOS cyclopentadiene-1-butane
- a solution of 4-chloro-l-methyl- (3.33 g, 20 mmol) in anhydrous THF (120 mL) is added dropwise a solution of tBuLi (1.6 N in heptane, 15.6 mL, 25 mmol) at ⁇ 65°C under nitrogen.
- tBuLi 1.6 N in heptane, 15.6 mL, 25 mmol
- the screen was performed as described in Vassal et al. (Vassal et al, 2006), HeLa cells were seeded at 36,000 cells per well of 96-well polystyrene tissue culture plates in 90 sL of medium and were allowed to grow for 24 hours. The following day each well was robotically supplemented with 10 ⁇ , of RPMI containing compounds (6,560) from the CNRS-Curie institute library. The final concentration of the compounds was 25 ⁇ . For bioactive controls, the final concentration was 5 ⁇ for paclitaxel and 2 ⁇ for colchicine. The final concentration of DMSO was 0.5%. After compounds dispense, cells were incubated 2 hours at 37°C S 5% C(3 ⁇ 4 in the workstation incubator.
- Cells were then permeabilized 10 minutes with 100 of warm OPT buffer, in order to eliminate free, depolymerized tubulin and fixed 6 minutes with 100 ⁇ , of methanol. Cells were then double stained for tyrosinated and detyrosinated tubulin using specific antibodies and fluorescent secondary antibodies. Nuclei were stained with Hoechst.
- Raw data were converted into percentage of tyrosinated/detyrosinated tubulin contents, based on plate controls averages.
- HMEC-GFP preparation
- HMEC-1 cells were infected by a defective retrovirus encoding for enhanced Green Fluorescent Protein (EGFP).
- EGFP Green Fluorescent Protein
- HMEC-1 clones expressing EGFP were selected in the presence of neomycin. Resistant clones were isolated by limit dilution, and amplified as independent lineages.
- HMECGFP herpetic Human Cytomegalovirus
- FfMEC-GFP cells were seeded at 3000 cells/well in round- bottom 96-multiwell plates in DME 1 g L glucose (Eurobio, Les Ulis, France) containing 0.25 % methylcellulose. 48 hours later, the spheroids were collected, transferred into flat- bottom 96-well plates and embedded io collagen gel (1.2 mg/mL type I collagen) prepared in a Iscove's modified Dulbecco's medium, supplemented with FGF-2 (10 ng mL), 50 ⁇ /mL penicillin and 50 Mg mL streptomycin.
- MDA-MB-231 cells were transfected with GFP-encoding plasmid pBGFP-Nl (Clonetech) using FuGENER reagent (Roche) and stable cells clones (MDA-MB231 -GFP) were selected. Fertilized White Leghorn eggs (SFPA, St. Brieuc) were incubated at 38°C with 60% relative humidity for 10 days. At this time (E10), the chorioallantoic membrane (CAM) was dropped by drilling a small hole through the eggshell into the air sac and a 1 cm 2 window was cut in the eggshell above the CAM.
- SFPA St. Brieuc
- Tumor cell lines HeLa human cervical adenocarcinoma
- MCF-7 human breast adenocarcinoma
- NCI-H460 human non small cell lung cancer
- 786-0 human renal adenocarcinoma
- MDA-MB-231 human breast carcinoma
- MES-SA human uterine sarcoma
- MES-SA Dx5 human uterine sarcoma
- HeLa, NC1-H460 MDA-MB-231, and 786-0 cells were grown in complete RPMI 1640 with GlutaMAXTM I (Gibco, Invitrogen) containing 10% fetal bovine serum (Hyclone, Thermo Fisher Scientific) and 100 units/mL of penicillin and 100 ]xg/mL of streptomycin (Gibco, Invitrogen).
- MCF-7 were maintained in EMEM (ATCC) with 10% fetal bovine serum, 100 units/mL of penicillin, 100 ⁇ ⁇ ⁇ of streptomycin and 0.1 mg/mL insulin (Sigma Aldrich).
- MES-SA and MES-SA DX5 were cultured in McCoy's 5 A (ATCC) supplemented with 10% fetal bovine serum and 100 units/mL of penicillin and 100 ⁇ .. of streptomycin during the first sub-culture, then adapted in Rl'MI 640 with GlutaMAXTM and 10% fetal bovine serum, 100 units/mL of penicillin and 100 ⁇ of streptomycin.
- HMEC-1 cells Human Microvascular Endothelial Cel!-1 were obtained from the Emory University.
- HMECGFP were derived from HMEC-1 by retroviral infection of a GFP-expressing construct and selection of a highly fluorescent cell clone that still expresses some of the major endothelial cell markers.
- HMEC-1 and HMEC-GFP were maintained in DMEM 1 g L glucose (Eurobio, Les Ulis, France) supplemented with 10% fetal calf serum (Biowest, Abcys, Paris, France).
- Human umbilical vein endothelial cells were purchased from Lonza (Basel,
- EGM-2-MV medium supplemented with 5% fetal calf serum (Cambrex, East Rutherford, NJ, USA). All cell lines were maintained at 37°C S 5% C0 2 humidity atmosphere in media.
- FGF-2 was from Salk Institute, La Jolla, CA, USA.
- HeLa cells grown for 72 hours on glass coverslips were incubated with or without compounds. After treatment, the culture medium was rapidly removed and cells were permeabifeed with OPT buffer (80 mM PIPES pH 6.7, 1 mM EGTA, 1 mM MgCI 2 , 0,5% Triton X-100 and 10% glycerol) for 3 minutes at 37°C.
- OPT buffer 80 mM PIPES pH 6.7, 1 mM EGTA, 1 mM MgCI 2 , 0,5% Triton X-100 and 10% glycerol
- This buffer allows the extraction of free tubulin dimers and preserves intact microtubules, when there are some. Ceils were then fixed by immersion in -20°C absolute methanol for 10 minutes. They were then processed for immunofluorescence as described in Paturle-Lafanechere et al, 1994.
- Fluorescence images were taken using a NIKON Eclipse 90i microscope and 100./ 1.3 Plan Neofluar objective, a CoolSNAPHQ2 Monochrome camera (Roper Scientific, Trenton, NJ) and NIS Elements software and were processed using Adobe Photoshop.
- GFP-EB3 plasmids were used because 1) EB3 as a stronger binding affinity to microtubule + end, and 2) the fusion of GFP to the N terminal part of EB1 strongly reduced its binding to microtubules as opposed to EB3, Cell transfection was performed using electroporation (AMAXA , Koln, Germany). 2 of purified plasmid DNA was used for each transfection reaction.
- Live imaging of microtubule plus ends was performed as described in Honore et al, 2011, on transiently GFP-EB3 transfected-HeLa cells by using an inverted fluorescence microscope (ZEISS Axiovert 200M with a 63X objective).
- Time-lapse acquisition was performed with a COOLSNAP HQ (Roper Scientific), driven by Metamorpii software (Universal Imaging Corp.). Images acquisition was performed at a temperature of 37 ⁇ 1°C / 5% CO ⁇ .
- the dynamic instability parameters analysis was performed by tracking microtubule plus end over time, using the image J software. The methods of calculation were as described in Honore et al, 201 1.
- HeLa cells grown for 72 hours on glass coverslips were incubated with compounds for 2 hours at indicated concentrations. After removal of the medium containing compounds, cells were rinsed 3 times with warm complete PMI medium and incubated overnight in complete RPMI medium. They were then processed for immunofluorescence, as described above.
- HeLa cells (1.10 6 ) seeded in 10 cm Petri dishes were grown for 2 days. They were incubated for 2 hours with the tested compound, and then washed with 2 mL of warm PBS. PBS was then carefully discarded and 1 mL of warm OPT buffer (Pipes 80 mM, EGTA 1 mM, MgCl 2 1 mM, triton X400 0.5% and glycerol 10% pH 6.8), containing the tested compound and proteases and phosphatases inhibitors (complete OPT buffer), was added. The dish was then gently shacked and the OPT buffer containing soluble tubulin dimers carefully recovered.
- OPT buffer Pipes 80 mM, EGTA 1 mM, MgCl 2 1 mM, triton X400 0.5% and glycerol 10% pH 6.8
- the remaining ceils content (containing the insoluble tubulin pool) was recovered in 1 mL of warm complete OPT buffer, using a cell scraper.
- the insoluble pool was kept at 4°C, sonicated and ultracentrifuged (200,000 g, 20 min, 4°C), in order to solubilize tubulin and to eliminate the DNA. Samples were then stored at -80°C.
- the same sample volume (20 uL) of soluble and insoluble pools was separated on an 8% polyacrylamide SDS-page gel and transferred onto nitrocelMose.
- Tubulin was detected using anti a ⁇ tubulin primary antibody (clone a3a (Peris et ⁇ , 2006)), monoclonal peroxidase-conjugated mouse secondary antibody (Sigma, A4 16) and detection with chimioluminescence kit ECLTM Plus (GE Healthcare, RPN2132).
- Cell proliferation was evaluated using the colorimetric 3-(4,5-dimetbylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide (MTT) assay (Sigma, M-5655).
- the assay was performed in 96 wells microplates (Greiner, #655086). Depending of the cell type and their rate of growth, cells were seeded at 20,000 to 50,000 cells per well and allowed to grow for 24 hours. The culture medium was then replaced with a fresh medium containing the drugs to be assayed at different concentrations or equivalent amounts of DMSO. Cells were allowed to grow for additional 48 hours.
- the medium was then discarded; cells were washed once with RPMI without phenol red and incubated for four hours with MTT (0.5 mg/mL) in RPMI without phenol red. At the end of the incubation period, the medium was removed and the converted dye solubilized with acidic isopropanol (isopropanol, 10% Triton XI 00, 0,1 N HC1). Absorbance of converted dye is measured at a wavelength of 570 nm, using FLUOstar Optima microplate reader.
- HeLa cells were grown in T25 flasks (5.1 5 cells per flask) and treated with DMSO colchicine or CMOl and CM02 for 16 hours. After treatment, non-adherent cells present in the medium were mixed with trypsinized adherent cells, centrifuged, washed twice with PBS- EDTA (2 mM) and fixed for 30 minutes with 1.5 mL 70% icecold ethanol Fixed cells were washed twice with PBS-EDTA, re-suspended in 0,5 mL DNA staining buffer (10 /mL propidium iodide, 10 g mL RNase A in PBS-EDTA 2 mM, pH 7.4) and incubated for 30 minutes in darkness. Cellular DNA was measured with a FACSCalibur flow cytometer (BD Biosciences). Data were analyzed using CellQuest software (BD Biosciences). Cells were gated by forward/side scattering from a total of 10,000 events.
- Microtubule protein (MTP) and pure tubulin were prepared according standard procedures (Paturle-Lafanechere et a!., 1991). Microtubule polymerization assay was adapted from (Bonne et 1985). Briefly, microtubule assembly was carried out in a half area 96- well black plate (Greiner, #675090) and followed using a microplate reader FLUOstar OPTIMA (BMG Labtechnologies).
- MTP MTP
- pure tubulin final concentration of 25 ⁇ and 30 ⁇ , respectively
- MME 00 mM MES, 1 mM gCl 2 , 1 mM EGTA, pH 6.75, for MTP
- PME buffer 100 mM PIPES, 1 mM MgC3 2j 1 mM EGTA, pH. 6.65, for pure tubulin
- 10 ⁇ DAPI variable concentrations of compounds to be assayed.
- MTP (3 ⁇ , final concentration) in PME buffer was mixed at G-4°C with compounds and tritiated competitor ([ 3 H] colchicine (76.5 Ci.mmol "1 , NEN) or [ 3 H vinblastine (9.6 Ci.mmol-l, Amersham Biosciences) in a final volume of 200 Following 30 minutes incubation at 30°C, mixtures were deposited onto 50 ⁇ of presedimented DEAE Sephadex A25 (to adsorb tubulin) in PME buffer. All subsequent steps were carried out at 0-4 C C. Samples were incubated for 10 min with continuous shaking to ensure quantitative binding of tubulin to the gel.
- EGM-2 medium (Cambrex) was allowed to polymerize at 37°C for 30 minutes in 48- multiwell plates. 3.105 HUVEC cells were seeded per well. Treatment with molecules (0.1, 1 and 10 ⁇ ) started right after cell attachment. Tubule formation was observed by phase- contrast microscopy at 24 hours.
- the assay used to screen the chemical library was based on the substrate properties of the tubulin modifying enzymes involved in the tubulin tyrosination cycle.
- the C- terminal tyrosine of the tubulin cc-subunii is removed by a cafbox peptidase and re-introduced by tubulin tyrosine ligase (TTL).
- TTL tubulin tyrosine ligase
- depolymerization or stabilization of the microtubule network can be easily distinguished by double-immunofluorescence staining using antibodies specific for tyrosinated and detyrosinated tubulin.
- This assay was used to screen a library of 6,560 compounds at 25 ⁇ concentration. 158 compounds belonging to several distinct structural families and able to lower the signal down to at least 75% in the tyrosinated tubulin channel as compared with DMSO-treated cells were selected. The normal Hoechst signal observed with these compounds is an indirect estimation of the integrity of the cell monolayer. These results indicated that these hits were potential microtubule depolymerizing agents.
- Table 1 Flow chart of the automated screening of the library and the subsequent analysis of active compounds
- the two potent 5-azaindole compounds of formula (I), CMOl and CM02 were more particularly studied as their scaffolds were drug-like, simple and their synthesis could give an easy access to numerous derivatives.
- Their effect on cellular microtubules was confirmed by immunofluorescence on HeLa cells fixed after permeabilization with OPT buffer. Whereas DMSO-treated cells exhibited a normal filamentous microtubule array, CM01/CM02 -treated cells were devoid of microtubules similarly to colchi cine-treated cells ( Figure 1A). The changes of tubulin polymerization status were also checked by performing sequential extraction of soluble and insoluble pools of cellular tubulin.
- the concentrations assayed were detennined after a preliminary immunofluorescence analysis of the compounds effect on the microtubule network.
- the concentrations chosen were in a range that induces a detectable but not total depolymerization of the microtubule network.
- CMOl and CM02 reduced the microtubule growth rate, increased time spent in pause and strongly reduced the microtubule growth length as indicated by the dose-dependent increase of the distance-based catastrophe frequency (Table 2).
- Table 2 Comparison of alteration of microtubule dynamic instability parameters induced by colchicine with that of CMOl and CMOl
- 5-Azaindole compounds of formula (I) are tubulin binders and compete with colchicines:
- tubulin is a target of azaindole derivatives
- in vitro microtubule polymerization assays were performed using either MTP or pure tubulin ( Figures 3 and 4).
- CMOl and CM02 inhibited tubulin polymerization in a dose-dependent manner.
- effect of CMG1 and CM02 on tubulin binding of [3H] colchicine and [ 3 H] vinblastine were investigated ( Figure 5).
- CMOl and CM02 selectively inhibited colchicine but not vinblastine binding on tubulin.
- CMOS C3 ⁇ 4 H H C ⁇ OH)Ph 100.2 82.6 were first conducted on in vitro tubulin assembly. The effects of the compounds were compared at a 25 ⁇ concentration. The requirements of the inter-aromatic group Z were first investigated, The inhibitory potencies of the compounds were the same when an ethane (CMOl), an ethylene (CM02) or a hydroxyethyl (CMOS) was present in this position. This result indicates that the nature of the group Z is not a stringent determinant. Position Ri can also be substituted by either a small group (methyl, CMOl and CM02) or by a larger one (benzyl, CM03 and CM04) without loss in inhibitory potency.
- CMOl ethane
- CM02 ethylene
- CMOS hydroxyethyl
- HeLa cells grown for 72 hours on glass coverslips were incubated with compounds at indicated concentrations for 2 hours. They were then processed with the immunofluorescence procedure for microscopy analysis described above (Table 4).
- 5-Azaindole compounds of formula (I) inhibit ceil proliferation of diverse cancer cell lines by promoting G2 M cell cycle arrest;
- GI50 (50% of growth inhibition) were in the sub- or 3ow-raicromoIar range regardless the tissue origins, p53 or K-ras status of the cells.
- CM01/CM02- treated cells were in the sub- or 3ow-raicromoIar range regardless the tissue origins, p53 or K-ras status of the cells.
- the distribution of CM01/CM02- treated cells in the cell cycle using flow cytometry was analyzed. Following 16 hours of exposure of the compounds at 1 ⁇ or 25 ⁇ , cells accumulated in G2/M phases (> 89%) when compared to vehicle-treated cells (23%, Figure 6).
- 5-azamdole compounds of formula (I) are potent cytostatic compounds, which block the cell cycle at G2/M phase.
- 5-AzaindoIe compounds of formula (I) overcome drug resistant (MDR) cell pheitotype:
- CMOl and CM02 The effect of CMOl and CM02 on cell proliferation of drug-sensitive sensitive cell- lines and of their drug-resistant counterparts that over-express the glycoprotein P or multidrug transporters such as ABCG2 and MRP] that confer cell resistance to multiple drugs (Marker et al, 1985) was compared (Table 5). CMOl and CM02 toxicity was found to be the same, with GI50 in the micromolar range, for the drug-sensitive human cell lines, and for their multidrug- resistant counterparts, indicating that it is not substrate of the glycoprotein V or of ABCG2 and MRPl transporters.
- 5-Azaindoles compounds of formula (I) exhibit a»ti-tumorai effect on an in vivo model of invasive breast cancer :
- MDA-MB-231 expressing GFP breast cancer cells xenografted on the chicken chorioallantoid membrane were used to assess both toxicity and efficiency of CMOl and CM02 molecules. Tumors treated with these compounds were significantly smaller (P ⁇ 0.05; Figure 9A and 9B). Furthermore, upon treatment, chicken embryos did not display significant increased mortality indicating that, in this model, these compounds are well tolerated at doses sufficient to induce antitumoral effect.
- the expression of GFP by the highly invasive MDA-MB-231 cells allowed an accurate detection, using fluorescence microscopy, of the dissemination of tumor cells in this model, as indicated by the number of nodules counted in the lower CAM ( Figure 9C) in DMSO-treated embryos. The nodule number was greatly reduced in CMOl and CM02 treated embryos, indicating that azaindoles derivatives affect invasion mechanisms.
- Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia. Biol Psychiatry. 60:1224- 30.
- MPC- 6827 a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res 67(12): 5865-5871.
- Taxol- resistant epithelial ovarian tumors are associated with altered expression of specific beta- rubulin isotypes. J Clin Invest 100(5): 1282-1293.
- Microtubules meet substrate adhesions to arrange cell polarity. Curr Opin Cell Biol 15(1): 40-47.
- Tozer GM Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, et al. (2001). Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 61(17): 6413-6422.
Abstract
The present invention relates to 5-azaindole type compounds responding to the following formula (I): for their use as drugs, and more particularly for the prevention and/or the treatment of diseases and/or disorders chosen amongst cancers; angiogenesis related disorders; parasitic diseases; fungal diseases; autoimmune diseases; inflammatory diseases; warts such as warts caused by papilloma virus. The invention also relates to pharmaceutical compositions comprising such compounds of formula (I). The use of at least one compound of formula (I) as research tool for the cell-cycle synchronization of microtubule drugs resistant cell lines is also part of the invention. Finally, the invention also concerns the use of at least one compound of formula (I) as an herbicide and/or an algaecide.
Description
5-AZAINDOLE COMPOUNDS WITH ANTICANCER AND ANTIANGIOGENIC ACTIVITIES
The present invention relates to 5-azamdole type compounds of formula (1) for their use as drags, more particularly for the prevention and/or the treatment of diseases and/or disorders chosen amongst cancers; aagiogenesis related disorders; parasitic diseases; fungai diseases; autoimmune diseases; inflammatory diseases; warts such as warts caused by papilloma virus. The present invention also relates to pharmaceutical compositions comprising such compounds of formula (I). The use of at least one compound of formula (I) as research tool for the cell-cycle synchronization of microtubule drugs resistant cell lines is also part of the invention. Finally, the present invention concerns the use of at least one compound of formula (I) as an herbicide and/or an algaecide.
Microtubules form, with the actin microfilaments and the intermediate filaments, the cytoskeleton of the eukaryotic cells. These are hollow tubular aggregates constituted of a single dimeric protein, i.e. the tubulin. In mammalian cells, the microtubule networks are in general nucleated at an organizing centre: the centrosome. These networks carry out multiple and vital roles such as organization of the cytoplasm, positioning of the organelles, cell motility and cell division. During mitosis, the microtubule network is reorganized to form the mitotic spindle, which is machinery used by cell to separate the duplicated chromosomes into two identical sets, before its cleavage into two daughter cells. Mitotic spindle integrity is controlled by specific checkpoints, Any undetected mitotic spindle dysfunction couid be at the origin of genomic instability and thus represents a potential source of tumorigenesis (Castillo et al, 2007; Kops et al, 2005).
Microtubules assemble by polymerization of α/β dimers of tubulin. Microtubules are highly dynamic polymers able to rapidly polymerize from free tubulin dimers and to depolymerize just as rapidly. Microtubule dynamics are crucial to mitosis (Jordan and Wilson, 2004; Niethammer et al, 2007).
The intrinsic microtubule dynamics is tightly regulated in the cell by interaction with an array of proteins that stabilize or destabilize microtubules, such as XMAP215 Disl/TOGp, MCAK, MAP4 and Opl8/stathmin (Holmfeldt et al, 2009; Kavallaris, 2010) or +TIPs (plus- end tracking proteins) such as EB1 (Akhmanova et al, 2005; Coquelle et al, 2009; Small et al, 2003). Targeted perturbation of this finely tuned process constitutes a major therapeutic strategy {Honore et al, 2005). Anti-mitotic drugs that interfere with the microtubule system are, indeed, key components of combination chemotherapies for the treatment of carcinomas (Kavallaris, 2010).
Perturbation of microtubule dynamics by drugs constitutes one of the most powerful ways to suppress (at least transiently) tumor growth. Despite their massive clinical use, most of these drugs have their therapeutic potential hampered by insufficient bioavailability and toxicity (myelosuppressi n, peripheral neurotoxicity). Moreover, failure in cancer therapy is often related to the selection of tumor cells that have acquired resistance against microtubule binding drugs. As a result, many efforts are undertaken to identify new chemical entities that may overcome those resistance mechanisms (5-amino-2-aroylquinolines (Nien et al, 2010), 1,2,4-triazole (Arora et al, 2009), for example).
Several anticancer drugs clinically important, including the Vinca alkaloids, vinblastine, vincristine, and vinorelbine and the taxanes paclitaxel and docetaxel specifically target tubulin and modify microtubules dynamics. Considering the clinical success of these agents, tubulin is today one of the best validated targets in anticancer chemotherapy (Giannakakou et al, 2000; Jackson et al, 2007; Zhou and Giarmakakou, 2005).
Furthermore, in addition to cancer, the involvement of the microtubule cytoskeleton in the etiology of a large number of diseases has been described, such as for example mental disorders (Andrieux et al, 2006; Andrieux et al, 2002; Begou et al, 2008) and neurodegenerative diseases (Denxtaut et al, 2005; Garcia et Cleveland, 2001), and viral (Ruthel et al, 2005), bacterial (Margalit et al, 2004) and parasitic (Morrissette and Sibley, 2002) infections. The pharmacological agents targeting the microtubule cytoskeleton and its various effectors may therefore exhibit a therapeutic advantage for the treatment of a large number of diseases (Lafanechere, 2008).
Thus, the treatments used in anticancer chemotherapy target, in a favored manner, the dynamic behavior of the microtubules. In particular, it may be blocked by many agents that can bind to different sites of tubulin. Structural data concerning the binding of these different agents on tubulin have been obtained. Zinc-induced sheets of paclitaxel-stabilized tubulin proto filaments have been used for construction of a model of tubulin with bound paclitaxel. After fitting this model into electron density microtubule maps, the authors concluded that paclitaxel binds to β-tubulin facing the microtubule lumen (Snyder et al, 2001). The X-ray structure of vinblastine bound to tubulin in a complex with the protein stathr n has shown that the vinblastine introduces a wedge at the interface of two tubulin molecules and thus interferes with tubulin assembly (Gigant et al, 2005),
These studies have led to the characterization, to date, of three binding sites of poisons of microtubules on tubulin: the domain of periwinkle alkaloids located at the interface between two /β-tubulin dimers, the site of taxoids located on the β subunit and that of
colchicine located at the interface between the a subunit and the β summit.
These various agents are classified according to whether they destabilize or stabilize the microtubules:
- Agents that destabilize the microtubules:
Periwinkle alkaloids, capable of depolymerizing the microtubules, have been identified as agents capable of arresting the cells in mitosis, with aberrant mitotic spindles. Subsequently, vincristine and vinblastine were introduced into clinical medicine in the 1960s and are still widely used in chemotherapy for testicular cancer, Hodgkin's disease or acute lymphoid leukemia,
Mention may also be made of colchicine or combretastatm, which inhibit the polymerization of the microtubules and also nocodazole.
- Agents that stabilize the microtubules, such as taxanes and epothilones:
Taxanes, and more particularly paclitaxel, interact specifically and reversibly with the microtubules with a stoichiometry of about one mole of taxane per one mole of tubulin. This interaction is accompanied by a stabilization of the microtubules.
Paclitaxel and the other taxanes are differentiated from other anti-tubulin poisons mainly by the stabilizing effect that they exert on the microtubules. Cancer drugs such as paclitaxel or Vinca alkaloids were previously thought to work through opposite mechanisms. There are now known to act by modifying microtubule dynamics, and not through increasing or decreasing the overall microtubule mass. Despite their antitumor efficacy, especially in breast cancer, ovarian cancer and lung cancer, taxanes are extremely toxic since they also act on the microtubules of non-cancerous cells in proliferation (hematopoietic cells, mucous cells, etc.). Finally, they may adversely affect the peripheral neurons and give rise to significant side-effects.
The therapeutic success of paclitaxel has maintained the advantage for the search for therapeutic agents that target tubulin.
However, although mostly valuable, the substances known from the prior art are not ideal. They have several side-effects, principally mye!osuppression and peripheral neurotoxicity. Neurotoxic side-effects related to tubulin drugs are not surprising because tubulin is a major player not only in cell division but also in mitosis-independent cytoskeietal functions.
Moreover, many cancers are inherently resistant to these drugs or become so during prolonged treatment. This phenomenon is a multifactorial process {Kavallaris, 2010; avallaris et al, 1997) but a common way for cancer cells to acquire drug resistance is the
expression of efflux pumps such as the glycoprotein P or ABCG2 and MRP1. Thus, identification of agents that are active in multidrug resistant (MDR) cells is urgently needed (Nien et al. , 2010).
Several strategies have been proposed for the development of potentially more effective and less toxic drugs. One is to improve existing drugs or to find new ones that target tubulin.
High-throughput, cell-based screening of small molecules is an attractive strategy to identify such agents. It enables the evaluation of the activity of compounds directly on cells, ruling out molecules that are not cell-permeable or too toxic. In the past few years, cell-based assays allowed the identification of several microtubule polymerization inhibitors such as 4- arylaminoquinazolines (Kasibhatla et aL, 2007) or Micropolyin (De Rycker et al., 2009).
By using a cell -based assay (Vassal et al, 2006), the Inventors have now surprisingly identified a new class of 5-azaindoles compounds of formula (I) as compounds that disrupt microtubule array in a reversible manner. Reversibility rules out the possibility of covalent bond formation between tubulin and azaindole derivatives. They have then discovered that these compounds bind directly to tubulin and impede colchicine binding, and that they also induced a G2/M cell cycle arrest and were toxic for a panel of cancer cell lines including multidrug-resistant cell lines. They have observed a complete microtubule depolymerization in cells, at concentrations of 0.05 to 1 μΜ. The identified 5-azaindole compounds of formula (I) displayed potent antiangiogenic properties and exerted anticancer effect
The first subject of the present invention thus relates to 5-azaindole compounds of formula (I):
CO
in which:
- the ring Ar is a C4-Ci2 aryl or beteroary] ring, preferably a phenyl or pyridine ring, and more preferably a phenyl ring,
- Rj = H, optionally substituted Ci-C6 alkyl, benzyl, arylsulfonyl, heteroarylsulfonyl, alkyloxycarbonyl or dialkylcarbamoyl groups, said substituents being independently
selected from halogen, hydroxyl, cyano, nitro, carboxylate, carboxyester, ammo, Ci-C^ alkyl, Ci-Q alkylamino, C2-C6 cycloamino or Ci-Q alkoxy groups,
- R2 represents H or a halogen atom, nitro, amino, Ci-Ce alkylamino or C2-C6 cycloamino groups, and preferably R2 = H or CI,
- ¾, R5, R$ and R7, identical or different, represent hydrogen or halogen atoms, hydroxyl, Ci-Ce alkyl, Ct-C6 alkoxy, cyano, nitro, carboxylate, carboxyester, amino, Cj-Q alkylamino or C2-C<, cycloamino groups, and preferably R3} Rs, R$ and R , identical or different, represent hydrogen atoms or Cj- e alkoxy groups,
- R4 = a halogen atom, hydroxyl, Ci-Cs alkoxy, amino, Cj-Cs alkylamino, C2-C6 cycloamino, thiol or Cj-Ce alkylthio groups, preferably R4 = a halogen atom or a C Q alkoxy group, and more preferably R = CI or a OCH3 group, and
- Z - C-CHR, CR'R" or C=0, wherein R = H or an optionally substituted Ci-C6 alkyl group, and R' and R", identical or different, represent hydrogen or halogen atoms, OH groups, CrCe alkyl or alkoxy groups, C4-Ci2 aryl, heteroaryl, arylalkyl or heteroarylalkyl groups, and preferably Z = C^HR or CR'R", wherein R = H or an optionally substituted CTC6 alkyl group, and R' and R", identical or different, represent hydrogen or halogen atoms, OH groups, Ci-Q alkyl or alkoxy groups, C4-C12 aryl, heteroaryl, arylalkyl or heteroarylalkyl groups.
or their tautomeric, racemic, enantiomeric or polymorphic forms or pharmaceutically- acceptable salts, for their use as drugs.
Surprisingly, the compounds of formula (I) of the invention were identified as compounds that disrupt microtubule array in a reversible manner. Reversibility rules out the possibility of covalent bond formation between tubulin and azaindoie derivatives. Since reversibility generally enables a better control of administrated compound dose during treatment, this characteristic is of importance for lead development. Biochemical experiments indicated that tubulin is an in vitro target of azaindoie derivatives and its polymerization inhibition is likely responsible for the observed phenotype. Complete microtubule depolymerization was observed in cells.
Competition assays using tritiated colchicine and vinblastine indicated that the compounds of formula (I) bind tubulin directly at a site that, at least partially, overlaps with the colchicine site. It cannot be excluded, however, that the compounds of formula (I) inhibit colchicine binding by an allosteric mechanism. Toxicity induced by colchicine treatment hampers its use as anti-cancer drug. Currently, there are no Food and Drug Administration- approved colchicine-binding site drugs used for the treatment of cancer. Combretastatins and
sulfonamides that bind to the same site are, however, presently undergoing Phase I and II clinical trials for solid tumors (Nien et al, 2010). This confirms the druggability of compounds targeting this binding site and supports azaindole derivatives as suitable leads for drug optimization. Testing several analogues identified essential features for tubulin binding and activity in cell. Since SAR established using cell-based assay may be biased by cel!ular permeability and stability of the tested compounds, a SAR analysis of the compounds effects on tubulin in vitro polymerization was conducted in parallel. These analyses gave similar results and indicated that positions Rj, R2 and interaromatic group Z are tolerant to substitution whereas alkoxy such as raethoxy in position R is required to get active compounds. Moreover, the observation that the in vitro SAR closely parallels the effects observed on cellular microtubule network supports the assumption that tubulin is the cellular target of the compounds of formula (I) of the invention.
Antiproliferative activities of the compounds of formula (I) revealed a broad spectrum of cytostatic effect with comparable efficiencies on cell lines with deficient p53 or overexpressing ~ras, both generic or epi genetic alterations that are among the most common alterations found in cancer ceils. In addition, contrary to many clinically used microtubule- binding drugs, the 5~azaindole compounds of formula (I) also exhibited antiproliferative activity in cell lines overexpressing the drug efflux pumps PgP, MRP1 and ABCG2, As the action of the compounds of formula (I) is reversible, these compounds may thus be used as research tool for cell synchronization experiments with resistant cells. Moreover, this property ma be exploited in the case of chemotherapeutic failure.
Flow cytometry analysis revealed that the compounds of formula (I) exert their antiproliferative action through cell cycle arrest in G2 M phase. Aneuploid cells were detected following treatment by the compounds of formula (I) of the invention. Induction of aneuploidy could be a concern since it promotes genetic instability. However, most if not all microtubule targeting compounds (for instance, vinca-alkaloids) induce aneuploidy but remains valuable drugs.
The compounds of formula (I) also inhibit angiogenic sprouting from microvascular endothelial cell spheroids, which demonstrates that these compounds exert anti angiogenic activity in vivo on tumor cells. The standard assays for evaluating the performance of anticancer drugs involve human tumor xenografts in immunodeficient mice. Tumors grown on the chorioallantoic membrane (CAM) of chicken embryos constitute, however, a fast, easy and affordable system for a first preclinical analysis of the compound effects. The highly vascularized nature of the CAM greatly promotes the efficiency of tumor cell grafting.
Remarkably, within 8 days not only do MDA-MB-231 tumor cells develop sizable tumors, but also they can escape the primary site, invade surrounding stroma, and reach distal portions of the CAM to form micro metastasis foci. Therefore, similar to some murine models, all steps of tumor growth and of the metastatic cascade are recapitulated in the chick embryo model but, importantly, in a very short period of time.
The administration of compounds of formula (I), at a concentration that does not affect the embryos development significantly reduce the tumors size, as compared to the vehicle (DMSO) treated-tumors, Furthermore, by comparing the number of nodules present in the lower CAM of embryos treated with compounds of formula (I) with those of vehicle-treated embryos, it was found that both compounds have antimetastatic properties.
The compounds of formula (I) are reversible microtubule depolymerizing agents that exert potent cytostatic effects on human cancer cells of diverse origins, including multidrug- resistant cells. Although they act in the micromolar range, their chemical structure is simpler than currently used microtubule polymerization inhibitors. The compounds of the invention also exhibit a significant inhibition of angiogenesis and tumor growth in chorioallantoid breast cancer xenografts.
In the sense of the present invention:
Alkyl groups are chosen among Cj.Ce alkyl groups such as methyl, ethyl, n- propyl, isopropyl, n-butyl, sec-butyl, tert-bxxtyl and isobutyl radicals;
- Alkoxy groups are chosen among Cj-Ce alkoxy groups such as methyloxy, ethyloxy, n-propyloxy, iso-propyloxy, n-butyloxy, sec-butyloxy, te^butyloxy and isobutyloxy radicals;
Aryl group means any functional group or substituent derived from at least one simple aromatic ring; an aromatic ring corresponding to any planar cyclic compound having a delocalized π system in which each atom of the ring comprises a p-orbital, said p-orbitals overlapping themselves. More specifically, the term aryl includes, but is not limited to, phenyl, biphenyl, 1 -naphthyl, 2-naphtyl, anthracyl, pyrenyl, and the substituted forms thereof. The aryl groups of the invention comprise preferably 4 to 12 carbon atoms, and more preferably 5 or 6 carbon atoms
- Heteroaryl group means any functional group or substituent derived from at least one aromatic ring as defined above and containing at least one heteroatom selected from P, S, O and N. The term heteroaryl includes, but is not limited to, furan, pyridine, pyrrole, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, tetrazole, pyridazole, pyridine, pyrazine, pyrimidine, pyridazine, benzofurane, isobenzofurane, indole, isomdole,
ben20thiophene, benzo[c]thiophenei benzimidazole, indazole, benzoxazole, benzisoxazole, benzothiazole, quinoline, isoqumolme, qumoxaline, qumazoliue, cinnoline, purine and acridine. The heteroaryl groups of the invention comprise preferably 4 to 12 carbon atoms, and more preferably 5 or 6 carbon atoms;
- Arylalkyl groups mean any group derived from an alkyl group as defined above wherein a hydrogen atom is replaced by an aryl as defined above;
Heteroaryialkyl groups mean any group derived from an alkyl group as defined above wherein a hydrogen atom is replaced by a heteroaryl group as defined above;
Alkylamino groups mean mono or di(CrC6)alkylamino group;
- Cycloamino groups mean C2-C6 cycloamino group such as aziridin-l-yl, azetidin-l-yl, pyrrolidm-l-yl, piperidm-l-yl, azepan-l-yl, tnorphoHn- -yi and thiomorpholin- -yI.
According to the invention, halogen atoms are chosen among bromine, chlorine, fluorine and iodine, preferably bromine, chlorine and fluorine, and more preferably chlorine.
The expression "pharmaceutically-acceptable" refers to compounds, materials, compositions and/or dosage forms which are suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other complications commensurate with a reasonable benefit/risk ratio.
Advantageously, in the compounds of formula (I): Z = C=C¾ or CR'R" with R' = H or OH and R" = d-C6 alkyl or phenyl groups, and preferably Z « C-CH2, CH(CH3), C(OH)C¾ or C(OH)C6H5.
It is noteworthy that:
- if Rj is an arylsulfonyl or a heteroarylsuifonyl group, preferably the aryl ring is a phenyl ring;
- if Ri is an alkoxycarbonyl group, preferably i is the butoxycarbonyl,
- if Rj is a dialkylcarbamoyl group, preferably i is the dimethylcarbamoyl.
According to an advantageous embodiment of the invention, R5 = CH3 or a benzyl group.
According to another advantageous embodiment of the invention, one of R j R5, R$ or R7 is a Ci-Q alkoxy group when the others are hydrogen atoms.
According to an alternative preferred embodiment, at least one of the R3, R5, ¾ or R7 radical is a OC¾ group. Preferably, Ar is a phenyl ring substituted by a OCH3 group in position 4.
The most preferred compounds of formula (I) according to the invention are the following:
CMOl
or
CM02
or
CMOS
or
CM04
CMOS
or
CM07
The present invention relates more particularly to compounds of formula (1) for their use for the prevention and/or the treatment of diseases and/or disorders chosen amongst cancers; angiogenesis related disorders; parasitic disease; fungal disease; autoimmune diseases; inflammatory diseases; warts such as warts caused by papilloma virus.
More particularly, the present invention relates to compounds of formula (I) for their use for the prevention and/or treatment of;
cancers chosen amongst testicular cancer, ovarian cancers lung cancer, breast cancer, Hodgkin's disease, acute lymphoid leukemia, neuroblastoma, melanoma, glioma, glioblastoma, sarcoma, colon cancer, pancreatic cancer,
angiogenesis related disorders chosen amongst diabetic blindness, macular degeneration, rheumatoid arthritis, psoriasis,
parasitic diseases involving apicomplexan parasites, parasites with ftagellum or cilia, toxoplasmosis,
autoimmune diseases chosen amongst multiple sclerosis, diabetic retinopathy, inflammatory diseases chosen amongst gout disease.
The compounds of formula (I) may be prepared for example according to the method described in Nguyen et al, 1986.
Another subject matter of the invention is a pharmaceutical composition comprising at least one compound of formula (I) according to the invention as an active principle, with at
least one pharmaceutically-acceptable excipient or carrier, and with at least another active substance.
The expression "pharmaceutically acceptable excipient" refers to any diluents, adjuvants or vehicles, such as preserving agents, fillers, disintegrating agents, wetting agents, emulsifying agents, suspending agents, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
The pharmaceutical composition of the present invention may be administered by any suitable route, for example, by oral, buccal, inhalation, sublingual, nasal, percutaneous, i.e. transdermal or parenteral (including intravenous, intramuscular, subcutaneous and intracoronary) administration. Therefore, the pharmaceutical composition of the invention can be provided in various forms, such as in the form of hard gelatin capsules, of capsules, of compressed tablets, of suspensions to be taken orally, of lozenges or of injectable solutions, ointments, or in any other form appropriate to the method of administration.
The pharmaceutical composition according to the invention includes those wherein a compound of formula (I) is administered in an effective amount to achieve its intended purpose. Determination of the effective amounts is well within the capability of those skilled in the art.
A "therapeutically effective dose" refers to that amount of compound of formula (I) which results in achieving the desired effect. Toxicity and therapeutic efficacy of compound of formula (1) can be easily determined by standard pharmaceutical procedures in cell cultures or experimental animals, i.e, for determining the LJ½ (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which is expressed as the ratio between LDso and ED50. The data obtained from such data can be used in formulating range of dosage for use in humans. The dosage of compound of formula (I) preferably lies within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed, and the route of administration.
The exact formulation, route of administration, and dosage can be chosen by the individual physician in view of the patient's conditions. Dosage amount and interval of administration can be adjusted individually to provide plasma levels of compound of formula (1) which are sufficient to maintain the preventive or therapeutic effects.
The amount of pharmaceutical composition administered will therefore depend on the subject being treated, on the subject's weight, the severity of the affliction and the manner of administration.
For human and other mammal use, the compounds of formula (I) can be administered alone, but they are preferably administered in admixture with at least one pharmaceutically acceptable carrier, the nature of which will depend on the intended route of administration and the presentation form... Pharmaceutical composition for use according to the present invention thus can be formulated in a conventional manner using one or more physiologically acceptable carriers comprising one or more excipient{s) and/or auxiliaries) that facilitate processing of the compounds of formula (I) into preparations which can be used pharmaceutically. Amongst the excipients and auxiliaries which can be used in the pharmaceutical composition according to the invention, one can mention anti-agglomerating agents, preservatives agents, dyes, vitamins, inorganic salts, taste-modifying agents, smoothing agents, coating agents, isolating agents, stabilizing agents, wetting agents, anti- caking agents, dispersing agents, emulsifying agents, aromas, penetrating agents, solubilizing agents, etc., mixtures thereof and generally any excipient conventionally used in the pharmaceutical industry.
By way of example, when the pharmaceutical composition is administered orally, the carrier may comprise one or several excipients such as talc, lactose, starch or modified starches, cellulose or cellulose derivatives, polyethylene glycols, acrylic acid polymers, gelatin, magnesium stearate, animal or vegetal fats of natural or synthetic origin, paraffin derivatives, glycols, etc.
For general information about the formulation and administration of pharmaceutical compositions, one can obviously refer to the book "Remington's Pharmaceutical Sciences", last edition. Of course, a person skilled in the art will take care on this occasion that the excipient(s) and/or auxiliary(ies) optionally used are compatible with the intrinsic properties attached to the pharmaceutical composition in accordance with the invention.
These pharmaceutical compositions can be manufactured in a conventional manner, i.e. by conventional mixing, dissolving, granulating, dragee-making, emulsifying, encapsulating, entrapping or lyophilizing processes. Proper formulation is dependent upon the route of administration chosen.
The use of at least one compound of general formula (I) as defined here-above as research tool for the cell-cycle synchronization of microtubule drugs resistant cell lines is also part of the invention.
Finally, the invention also concerns the use of at least one compound of general formula (I) as defined here-above as an herbicide and/or an algaecide.
Besides the preceding provisions, the invention also comprises other provisions which will emerge from the remainder of the description which follows, which relates to examples that highlight the anticancer and antiangiogenic effects of the 5-azaindole compounds of formula (I), and also to the appended drawings in which:
- Figure t shows the effect of two compounds of formula (I) according to the invention, CMOI and CM02, on microtubule network organization: (A) Immunofluorescence analysis of cell microtubules. HeLa cells were incubated for 2 hours with 0.25% DMSO (A, vehicle control); 5 μΜ colchicine (B); 25 μΜ CMOI (C) or 25 μΜ CM02 (D). Cells were then permeabilized, fixed and stained for tubulin as described in Material and Methods. Nuclei were stained with Hoechst Bar = 10 μηι. (B) a-tubulin partition between soluble and insoluble fractions. HeLa cells were treated for 2 hours with 0.25% DMSO (vehicle control); 2 μΜ colchicine and increasing concentrations of CMOI as indicated. Insoluble (I) and soluble (S) fractions were prepared as described in Materials and Methods. Equivalent volumes of extracts (20 μΐ,) were separated on 8% SDS-PAGE, and subjected to immunoblot analysis using monoclonal antibody specific for total a-tubulin. (C) same as (B), but with CM02.
- Figure 2 shows the reversibility of CMOI and CM02 effects in HeLa cells. HeLa cells were treated for 2 hours with 0.25% DMSO (control); 5 μΜ colchicine; 10 μΜ nocodazole, 25 μΜ nocodazole, 25 μΜ CMOI or 25 μΜ CM02, as indicated. Compounds were the removed removal and cells were incubated overnight in fresh medium. They were then fixed and stained for a-tubulin,
- Figure 3 shows the effect of CMOI and CM02 on microtubule polymerization in vitro". MTP tubulin polymerization assay. Tubulin was allowed to polymerize at 37°C, at the indicated conditions. Fluorescence of DAPI bound to microtubule was measured to monitor microtubule polymerization. Experiments were performed in triplicate, in the presence of increasing concentration of CMOI or CM02, as indicated. Results are presented as mean ± standard error of the mean (SEM).
- Figure 4 shows the effect of CMOI and CM02 on microtubule polymerization in vitro: Pure tubulin polymerization assay. Tubulin was allowed to polymerize at 37°C, at the indicated conditions. Fluorescence of DAPI bound to microtubule was measured to monitor microtubule polymerization. Experiments were performed in triplicate, in the presence of increasing concentration of CMOI or CM02, as indicated. Results are presented as mean ±
standard error of the mean (SEM).
- Figure 5 represents the effect of CMOl and CM02 on the binding of [3H] colchicine and f H] vinblastine to microtubule proteins. 50 nM [3H] colchicine (black bars) or 30 nM [¾] vinblastine (dashed bars) were competed with 100 μΜ of CMOl, CM02, colchicine and vinblastine as described in Materials and Methods. Each value represents the mean ± SEM from triplicate determinations.
- Figure 6 represents the cell cycle distribution upon treatment of HeLa cells with CMOl and CM02. HeLa cells were incubated for 16 hours with DMSO (control), colchicine (2 μΜ), CMOl and CM02 (1 μΜ and 25 μΜ, as indicated). Cell cycle parameters were analyzed by flow cytometry, as described in Materials and Methods. The upper panel shows the graphs obtained for 1 and 25 μΜ, as indicated, of CMOl and CM02 (black), compared with that obtained for DMSO (grey). Values (lower table) are expressed as percentage of the total cell population,
- Figure 7 shows that the compounds of formula (I) inhibit capillary-like tube formation. HUVEC cells were seeded on Matrigel and compounds, at the indicated concentrations were added after cell attachment (one hour later). Tubule formation was observed by phase-contrast microscopy at 24 hours. Bar = 200 μιη.
- Figure 8 represents the quantitative analysis of endothelial sprouting in response to 5-azaindoles compounds of formula (I). FGF2 (100 ng/ nL) was added at day 0 to collagen- embedded HMEC-GFP spheroids in the presence of CMOl and CM02 at different concentrations (Ο.ί μΜ to 25 μΜ). After 3 days of culture, the spheroids were observed under an epifluorescence microscope: (A) Overlay of phase contrast and fluorescence observations at the indicated concentrations of compounds. (B) Measure of the mean total sprout length of endothelial spheroids, performed by quantitative microscopy image analysis. In each condition, data represent the mean values ± SE of multiple spheroids (n > 10) from one representative experiment out of two.
- Figure 9 shows the anti-tumoral effect of 5-azaindoles compounds of formula (I); MDA-MB-231 cells were xenografted on chick embryo chorioallantoic membrane (CAM). After treatment with either vehicle (DMSO), colchicine, CMOl or CM02, tumors were excised and weighted. The lower CAM was also dissected, fixed and the number of GFP- fhiorescent nodules was counted, as described in the material and methods section. A) Representative pictures of tumors at the end of the different treatments. B) Effect of the different treatments on tumors weight (means ± SE of 6 samples), C) Effect of the different treatments on the nodule number detected in the lower CAM (means ± SE of 6 samples).
* p < 0,05; ** p < 0.01 , significantly different from control values using Mann-Witney test. Bar = 0.8 mm.
MATERIAL AND METHODS:
1) Synthesis
(R,S) 4-chloro-2-(l-(4-methoxyphenyl)ethyl)-!-meihyl-lH-pyn:olo[3J2-c]pyridine
(CMOl), 4~chloro-2-(l-(4-methoxyphenyl)vinyl)-l-methyl-lH-pyrrolo 3,2-c]pyridine (CM02), (R,S) 1 -benzy]-4-chloro~2-(l-(4-methoxyphenyl)emyl)-lH-pyrrolo[3,2-c]pyridine (CM03), l-ben2yl-4-chloro-2-(i-(4~mel3ioxyphenyl)vmyl)-3H'pyrroIo[3,2-c]pyridine (CM04), (R,S) l-(4-chloro-l -methyUH-pyirolofS^-iilpvridine^-yl)- 1 -(4- methoxyphenyl)ethanol (CMOS) and (R,S) 4-chloro-l-methyl-2-(l-phenylethyl)-lH- pyrroio[3,2-c]pyridine (CM06) were synthetized according to the method published in Nguyen et at., 1986.
The procedure to obtain the compound (R,S) 3,4~dichloro-2-(l-(4- methoxyphenyl)ethyl)-l-methyl~lH-pyrrolo[3,2-c3pyridine (CM07) is the following: a solution of 2-(l~(4-memoxyphenyl)ethyl)"l-methyl-lH-pyrrolo[392-c]pyridin-4(5H)-one (prepared as described in Nguyen et al, 1986, 500 mg, 1.8 mmol) and PCls (320 mg, 1.8 mmol) in POCl3 (50 mL) was heated under reflux for 2.5 h. After evaporation into dryness under vacuum, cold water (100 mL) was added and the medium was rendered basic by addition of 2S% ammonium hydroxide (4 mL). The aqueous layer was extracted by CH2CI2 and the organic layer was washed with brine, dried over MgS04 and evaporated under vacuum. The residue was purified by flash chromatography (silica, CH2Cl2/EtOH; 95/5) to give the expected compound as beige solid (300 mg, 56%), p 170°C Elemental Analysis Cl7Hj6Cl2N20; Calculated: C, 60.89; H, 4.78; CI, 21.19; N, 8.36; Found: C, 60.73: H, 4.92; CI, 20.89; N, 8.23,
The procedure to obtain the compound (R,S) ^ch!oro-l-methyl-lH-pyrrolo ^- c]pyridin-2-yldiphenylmethanol (CMOS) is the following: to a solution of 4-chloro-l-methyl-
(3.33 g, 20 mmol) in anhydrous THF (120 mL) is added dropwise a solution of tBuLi (1.6 N in heptane, 15.6 mL, 25 mmol) at ~65°C under nitrogen. The mixture is stirred at the same temperature for 10 min. A solution of benzophenone (3.6 g, 20 mmol) in THF (20 mL) is then added dropwise and the resulting solution stirred at -20 °C for 30 min, and then at room temperature for 2 hours. Then, 250 mL of 4 N HQ solution is added and the precipitate is collected by filtration after 18 hours stirring at room temperature and washed with water. Recrystallized from ethanol gives the pure expected compound (5.6 g,
80% yield), mp 258°C. Elemental Analysis C2iHi7ClN20; Calculated; C, 72.31 ; H, 4.91; CI, 10.16; N, 8.03; Found: C, 72.24; H, 5.04; CI, 9.98; N, 7,84.
CM09
The procedure to obtain the compound (R.S) l-^-methoxy-l-me yl-lH-pyrroloP^- c]pvridine-2-yl) -(pyridine-4~yl)ethanol (CM09) is the following: to a solution of 4- methoxy-l-methyl-lH-pyrrolofS^-eJpyridine (3.24 g, 20 mmol) in anhydrous THF (100 mL) was added dropwise a solution of tBuLi (2.2 N in heptane, 11.4 mL, 25 mmol) at -55°C under nitrogen. The mixture was stirred at this temperature for 5 min and then at -15 C for 10 min. A solution of 4~acetylpyridine (3,63 g, 30 mmol) in THF (10 mL) was then added dropwise at -55°C and the resulting solution stirred at this temperature for 1 h and then left at 20°C overnight. Successively, a solution of 0.5 N HC1 (200 mL) and C¾C12 are added. The organic layer is discarded and the aqueous phase was rendered basic by addition of solide NaHC03. The precipitate was collected by filtration, washed with water, dried and recrystaUrzed from toluene gave the expected compound (4.8 gf 84% yield), mp 232-4°C. Elemental Analysis C16H17N3O2 O.2 C6H5CH3; Calculated: C, 69.28; H, 6.17; N, 13,93; Found: C, 69.35; H, 6.19; N, 14.05.
The procedure to obtain the compound 4-methoxy-2-(l-(4-methoxyphenyl)vinyl)-l- methyl-lH-pyrrolo[3,2-c]pyridine (CM10) is the following:
The mixture of 4-chloro-2-(l-(4-methoxyphenyl)vmyl)-l-methyl-lH-pyrrolo[352- ejpyridine (obtained as described in Can J. Chem (1986), 64, 545, 310 mg), 24% solution of sodium methoxide in methanol (20 mL) and D F (6 mL) was heated under reflux for 24h. 70 mL of water was added and the organic layer obtained after extraction using dichloromethane was dried over MgS0 and evaporated in vacuum into dryness to give the title compound (290 mg, 95% yield).
Ή NMR (CDCI3) δ 7.89 (d, 1H), 7,23 (d, 1H), 6.90-6.85 (m, 3H), 6.65 (s, 1H), 5.70 (s, 1H), 5.42 (s, 1H), 4.10 (s, 3H), 3.81 (s, 3H), 3.36 (s, 3H).
Microanalyses, calculated for C[sHi8N202- 0.25 ¾0: C, 72.36; H, 6.20; N, 9.38; found: C, 71.57; H, 6.26; N, 9.37.
The procedure to obtain the compound 1 -(4-chIoro~ 1 -(phenylsulfonyl)- 1 H-indol-2-yl)- l-(4-methoxyphenyl)ethanol (CM11) (representative of the prior art) is the following:
R-Butyllithium (1.6 M in hexane, 7.5 mL, 12 mmol) was added dropwise at -78 °C to a solution of the 4-chloro-l -phenylsulfonyl- lH-indole obtained as described by S. Maliboobi (J. Med. Chem. 2006, 49, 3101-31 15) (3,0 g, 10.3 mmol) in dry THF (30 mL). After 1h on stirring, acetophenone (2.1 g, 14 mmol) in THF (10 mL) was added at the same temperature and the mixture was kept at room temperature overnight The mixture was poured into IN HC1 (70 mL), the aqueous solution was extracted with dichloromethane and the organic layer was washed with brine, dried over MgS(¾ and evaporated in vacuum. Ethanol (10 ml) was added and the solid was collected, washed with minimum amount of ethanol and dried in the air giving l~(4-chloro-l-(phenylsulfonyl)-lH-mdol-2-yl)-l-(4-methoxyphenyl)ethanol (3.2 g, 70% yield).
Ή NMR (DMSO-- ) δ 7.51 (d, 1H), 7.65-7.53 (m, 3H), 7.48-7.30 (m, 4H), 7.20 (d, 2H), 7.06 (s, 1H), 6.82 (d, 2H), 5.77 (s, 1H), 3.74 (s, 3H), 1.94 (s, 3H).
Microanalyses, calculated for C23H20CINO4S: C, 62.51; H, 4.56; N, 3.17 ; found: C5
62.46; H, 4.66; N, 3.11.
The procedure to obtain the compound 4~chloro-2-(l-(4-methoxyphenyl) vinyl)- 1- (phenylsulfonyl)-lH-indol (CM12) (representative of the prior art) is the following:
CI
The mixture of l-(4-chloro-l-(phenyls lfonyl)-lH-indol-2-yl)-l-(4- methoxyphenyl)ethanol (2.3 g, 5.2 mmol), benzyltriethylammoniiim chloride (5.0 g, 22 rnmol), phosphoryl trichloride (5.6 mL, 60 mmol) and acetonitrile (60 mL) was heated under reflux, for 18 h. The volatile material was evaporated in vacuum, cold water (100 mL) was added and the medium was basified by addition of sodium hydroxide (2 N). The precipitate was collected by filtration, washed with water. It was suspended in water, extracted by dichorom ethane. The organic layer was dried over MgS0 and evaporated in vacuum to give the intermediate 234-ch]oro»2-(l-(4-methoxyphenyl)vinyl)-l-(phenylsulfonyl)-lH-indoIe (2.2 g, 100% yield).
¾ NMR (DMSO-i¾ δ 8.06-8.00 (m ΪΗ), 7.70-7.60 (m, 3H), 7.50 (d, 2H), 7.43-7.36
(m, 2H), 7.18 (d, 2H), 6.93-6.83 (m, 3H), 5.88 (s, 1H), 5.46 (s, 1H), 3.76 (s, 3H).
The procedure to obtain the compound 4-chloro-2-(l-(4-methoxyphenyl)vinyl)-l.H- indole (CM13) (representative of the prior art) is the following:
The mixture of 4-chloro-2-(l-(4-methoxyphenyl)vinyl)-l-(phenylsuIfonyl)-lH-indole (500 mg, 1.2 mmol), 10% NaOH (40 mL) and EtOH (80 mL) was heated under reflux for 2.5 L 30 mL of water was added and the organic layer obtained after extraction using dichioromethane was dried over MgS04 and evaporated in vacuum to give the intermediate 3, 4-chioro-2-(l-(4~methoxyphenyl)vinyl) H-indole (314 mg, 94% yield).
lM NMR (DMSO< ) 6 11.72 (s 1H), 7.57-7.38 (m, 3H), 7.25-7.02 (m, 4H), 6.28 (s, 1H), 5.83 (s, 1H), 5.43 (s, 1H), 3.87 (s, 3H).
Ten millimolar stock solutions were prepared in DMSO and kept at -20°C. Appropriate dilutions were freshly prepared prior to use.
Methods:
Screening:
The screen was performed as described in Vassal et al. (Vassal et al, 2006), HeLa cells were seeded at 36,000 cells per well of 96-well polystyrene tissue culture plates in 90 sL of medium and were allowed to grow for 24 hours.
The following day each well was robotically supplemented with 10 μί, of RPMI containing compounds (6,560) from the CNRS-Curie institute library. The final concentration of the compounds was 25 μΜ. For bioactive controls, the final concentration was 5 μΜ for paclitaxel and 2 μΜ for colchicine. The final concentration of DMSO was 0.5%. After compounds dispense, cells were incubated 2 hours at 37°CS 5% C(¾ in the workstation incubator. Cells were then permeabilized 10 minutes with 100
of warm OPT buffer, in order to eliminate free, depolymerized tubulin and fixed 6 minutes with 100 μΐ, of methanol. Cells were then double stained for tyrosinated and detyrosinated tubulin using specific antibodies and fluorescent secondary antibodies. Nuclei were stained with Hoechst.
Fluorescence was measured using the FLUOstar Optima microplate reader (BMG), with suitable filters for each wavelength. Raw data were converted into percentage of tyrosinated/detyrosinated tubulin contents, based on plate controls averages.
Linear regression based on plate controls averages was realized to reduce the impact of plate effects. Active compounds selected by this primary screen were retested from freshly made solutions.
HMEC-GFP preparation:
HMEC-1 cells were infected by a defective retrovirus encoding for enhanced Green Fluorescent Protein (EGFP). A DNA constructs encoding both the EGFP coding sequence under the control of the herpetic Human Cytomegalovirus (HCMV) promoter and the neo gene (vector pEGFP-Nl, Clontech) was cloned into the pLNCX vector. This vector was integrated in PT67 cells by transfection with Effectene (Qiagen). PT67 cell superaatants were used to infect HMEC-1 cells. HMEC-1 clones expressing EGFP were selected in the presence of neomycin. Resistant clones were isolated by limit dilution, and amplified as independent lineages. One cell line strongly expressing EGFP protein was named HMECGFP.
Sprouting of HMEC-GFP:
To prepare spheroids, FfMEC-GFP cells were seeded at 3000 cells/well in round- bottom 96-multiwell plates in DME 1 g L glucose (Eurobio, Les Ulis, France) containing 0.25 % methylcellulose. 48 hours later, the spheroids were collected, transferred into flat- bottom 96-well plates and embedded io collagen gel (1.2 mg/mL type I collagen) prepared in a Iscove's modified Dulbecco's medium, supplemented with FGF-2 (10 ng mL), 50 μ/mL penicillin and 50 Mg mL streptomycin. Treatment with two concentrations (25 μΜ and 12.5 μΜ) of CMOl and CM02 started right after spheroids were included in the collagen gels. Sprouting was allowed for 24 hours at 37°C. Images were acquired by fluorescence
microscopy and analysis of gel invasion was performed using the freeware ImageJ (http://Tsbweb.nih.gov/ij/). Statistical analysis was performed using a Kruskal & Wallis test.
Chick embryo tumors growth and metastasis assay:
MDA-MB-231 cells were transfected with GFP-encoding plasmid pBGFP-Nl (Clonetech) using FuGENER reagent (Roche) and stable cells clones (MDA-MB231 -GFP) were selected. Fertilized White Leghorn eggs (SFPA, St. Brieuc) were incubated at 38°C with 60% relative humidity for 10 days. At this time (E10), the chorioallantoic membrane (CAM) was dropped by drilling a small hole through the eggshell into the air sac and a 1 cm2 window was cut in the eggshell above the CAM.
Cultured MDA-MB231 -GFP were detached by trypsinization, washed with complete medium and suspended in serum free DMEM. A 50 μΐ, inoculum of 1.106 MDA-MB-231 - GFP cells was added directly onto the CAM of each egg. Eggs were then randomized in 4 groups of 12 eggs (to get sufficient surviving embryos at the end of the experiments). Two days later, tumors began to be detectable. They were then treated during 8 days, every two days (El 2, E14, E 16, El 8), by dropping 100 ]x of either 50 μΜ CMOl, 50 μΜ CM02, 2 μΜ colchicine or 0.5 % DMSO (vehicle) in PBS onto the tumor. The slow dropping on the large tumor area that depresses the CAM surface was found appropriate enough to avoid the leakage and dispersion of the compounds. Then, windows were sealed with cellophane tape and the eggs were returned to the incubator. At El 9 the upper portion of the CAM was removed, transferred in PBS and the tumors were then carefully cut away from normal CAM tissue. Tumors were then quickly dried on cellophane before weighing. In parallel, a 1 cm2 portion of the lower CAM was collected to evaluate the number of nodules, containing GFP- expressing cells. The fluorescent nodule were visualized in situ using whole mounts of tissue fixed in 4% formaldehyde in PBS and flattened between a hollow glass slide and a thick coverslip. A thorough and complete visual scan of the piece of the lower CAM was done using Leica Macro fluo fluorescent microscope (Optimal, Grenoble). Digital color images were acquired using DP25 camera on SZ 10 microscope (Olympus, France).
Cell Lines and Culture:
Tumor cell lines HeLa (human cervical adenocarcinoma), MCF-7 (human breast adenocarcinoma), NCI-H460 (human non small cell lung cancer), 786-0 (human renal adenocarcinoma), MDA-MB-231 (human breast carcinoma), MES-SA (human uterine sarcoma) and the multiple drug resistant cell line MES-SA Dx5 (human uterine sarcoma) were originally obtained from American Type Culture Collection (Rockville, MD). HeLa, NC1-H460 MDA-MB-231, and 786-0 cells were grown in complete RPMI 1640 with
GlutaMAX™ I (Gibco, Invitrogen) containing 10% fetal bovine serum (Hyclone, Thermo Fisher Scientific) and 100 units/mL of penicillin and 100 ]xg/mL of streptomycin (Gibco, Invitrogen). MCF-7 were maintained in EMEM (ATCC) with 10% fetal bovine serum, 100 units/mL of penicillin, 100 ^ηιί of streptomycin and 0.1 mg/mL insulin (Sigma Aldrich). MES-SA and MES-SA DX5 were cultured in McCoy's 5 A (ATCC) supplemented with 10% fetal bovine serum and 100 units/mL of penicillin and 100 ^ιηΐ.. of streptomycin during the first sub-culture, then adapted in Rl'MI 640 with GlutaMAX™ and 10% fetal bovine serum, 100 units/mL of penicillin and 100 ^πΛ of streptomycin. HMEC-1 cells (Human Microvascular Endothelial Cel!-1) were obtained from the Emory University. HMECGFP were derived from HMEC-1 by retroviral infection of a GFP-expressing construct and selection of a highly fluorescent cell clone that still expresses some of the major endothelial cell markers. MDA-MB-231-GFP (CNRS UMS 3453), HMEC-1 and HMEC-GFP were maintained in DMEM 1 g L glucose (Eurobio, Les Ulis, France) supplemented with 10% fetal calf serum (Biowest, Abcys, Paris, France).
Human umbilical vein endothelial cells (HUVEC) were purchased from Lonza (Basel,
Switzerland) and cultured in EGM-2-MV medium supplemented with 5% fetal calf serum (Cambrex, East Rutherford, NJ, USA). All cell lines were maintained at 37°CS 5% C02 humidity atmosphere in media. FGF-2 was from Salk Institute, La Jolla, CA, USA.
Immunofluorescence procedure for microscopy analysis:
HeLa cells grown for 72 hours on glass coverslips were incubated with or without compounds. After treatment, the culture medium was rapidly removed and cells were permeabifeed with OPT buffer (80 mM PIPES pH 6.7, 1 mM EGTA, 1 mM MgCI2, 0,5% Triton X-100 and 10% glycerol) for 3 minutes at 37°C. This buffer allows the extraction of free tubulin dimers and preserves intact microtubules, when there are some. Ceils were then fixed by immersion in -20°C absolute methanol for 10 minutes. They were then processed for immunofluorescence as described in Paturle-Lafanechere et al, 1994.
Fluorescence images were taken using a NIKON Eclipse 90i microscope and 100./ 1.3 Plan Neofluar objective, a CoolSNAPHQ2 Monochrome camera (Roper Scientific, Trenton, NJ) and NIS Elements software and were processed using Adobe Photoshop.
Transfection of GFP-EB3:
To label microtubule plus ends, GFP-EB3 plasmids were used because 1) EB3 as a stronger binding affinity to microtubule + end, and 2) the fusion of GFP to the N terminal part of EB1 strongly reduced its binding to microtubules as opposed to EB3, Cell transfection was
performed using electroporation (AMAXA , Koln, Germany). 2 of purified plasmid DNA was used for each transfection reaction.
Fluorescence time-lapse videomicroscopy of microtubule plus ends:
Live imaging of microtubule plus ends was performed as described in Honore et al, 2011, on transiently GFP-EB3 transfected-HeLa cells by using an inverted fluorescence microscope (ZEISS Axiovert 200M with a 63X objective). Time-lapse acquisition was performed with a COOLSNAP HQ (Roper Scientific), driven by Metamorpii software (Universal Imaging Corp.). Images acquisition was performed at a temperature of 37 ± 1°C / 5% CO^.
To study colchicine, CMOl and CM02 effects on microtubule dynamics, cells were incubated with different concentrations of compounds, or vehicle alone (DMSO) for 2 hours. Data are from 3 independent experiments. For each experiment, 6 microtubules/cell in 6 cells per condition were analyzed.
Dynamic instability parameters analysis:
The dynamic instability parameters analysis was performed by tracking microtubule plus end over time, using the image J software. The methods of calculation were as described in Honore et al, 201 1.
Drug reversibility assay:
HeLa cells grown for 72 hours on glass coverslips were incubated with compounds for 2 hours at indicated concentrations. After removal of the medium containing compounds, cells were rinsed 3 times with warm complete PMI medium and incubated overnight in complete RPMI medium. They were then processed for immunofluorescence, as described above.
Fractionation of extracts and immunoblotting:
HeLa cells (1.106) seeded in 10 cm Petri dishes were grown for 2 days. They were incubated for 2 hours with the tested compound, and then washed with 2 mL of warm PBS. PBS was then carefully discarded and 1 mL of warm OPT buffer (Pipes 80 mM, EGTA 1 mM, MgCl2 1 mM, triton X400 0.5% and glycerol 10% pH 6.8), containing the tested compound and proteases and phosphatases inhibitors (complete OPT buffer), was added. The dish was then gently shacked and the OPT buffer containing soluble tubulin dimers carefully recovered. After a 1 mL wash with the same buffer, the remaining ceils content (containing the insoluble tubulin pool) was recovered in 1 mL of warm complete OPT buffer, using a cell scraper. The insoluble pool was kept at 4°C, sonicated and ultracentrifuged (200,000 g, 20 min, 4°C), in order to solubilize tubulin and to eliminate the DNA. Samples were then stored at -80°C. For western blot analysis, the same sample volume (20 uL) of soluble and insoluble
pools was separated on an 8% polyacrylamide SDS-page gel and transferred onto nitrocelMose. Tubulin was detected using anti a~tubulin primary antibody (clone a3a (Peris et αί, 2006)), monoclonal peroxidase-conjugated mouse secondary antibody (Sigma, A4 16) and detection with chimioluminescence kit ECL™ Plus (GE Healthcare, RPN2132).
Cell proliferation assay:
Cell proliferation was evaluated using the colorimetric 3-(4,5-dimetbylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide (MTT) assay (Sigma, M-5655). The assay was performed in 96 wells microplates (Greiner, #655086). Depending of the cell type and their rate of growth, cells were seeded at 20,000 to 50,000 cells per well and allowed to grow for 24 hours. The culture medium was then replaced with a fresh medium containing the drugs to be assayed at different concentrations or equivalent amounts of DMSO. Cells were allowed to grow for additional 48 hours. The medium was then discarded; cells were washed once with RPMI without phenol red and incubated for four hours with MTT (0.5 mg/mL) in RPMI without phenol red. At the end of the incubation period, the medium was removed and the converted dye solubilized with acidic isopropanol (isopropanol, 10% Triton XI 00, 0,1 N HC1). Absorbance of converted dye is measured at a wavelength of 570 nm, using FLUOstar Optima microplate reader.
Cell cycle analysis:
HeLa cells were grown in T25 flasks (5.1 5 cells per flask) and treated with DMSO colchicine or CMOl and CM02 for 16 hours. After treatment, non-adherent cells present in the medium were mixed with trypsinized adherent cells, centrifuged, washed twice with PBS- EDTA (2 mM) and fixed for 30 minutes with 1.5 mL 70% icecold ethanol Fixed cells were washed twice with PBS-EDTA, re-suspended in 0,5 mL DNA staining buffer (10 /mL propidium iodide, 10 g mL RNase A in PBS-EDTA 2 mM, pH 7.4) and incubated for 30 minutes in darkness. Cellular DNA was measured with a FACSCalibur flow cytometer (BD Biosciences). Data were analyzed using CellQuest software (BD Biosciences). Cells were gated by forward/side scattering from a total of 10,000 events.
Tubulin polymerization assay:
Microtubule protein (MTP) and pure tubulin were prepared according standard procedures (Paturle-Lafanechere et a!., 1991). Microtubule polymerization assay was adapted from (Bonne et 1985). Briefly, microtubule assembly was carried out in a half area 96- well black plate (Greiner, #675090) and followed using a microplate reader FLUOstar OPTIMA (BMG Labtechnologies). Wells were charged with either MTP or pure tubulin (final concentration of 25 μΜ and 30 μΜ, respectively) in MME ( 00 mM MES, 1 mM
gCl2, 1 mM EGTA, pH 6.75, for MTP) or PME buffer (100 mM PIPES, 1 mM MgC32j 1 mM EGTA, pH. 6.65, for pure tubulin) with 10 μΜ DAPI and variable concentrations of compounds to be assayed. Following 10 minutes incubation, assembly was initiated by injection of GTP and MgCl2 to a final concentration of 1 mM and 5 mM respectively, yielding a reaction volume of 100 μΐ,, The excitation and emission wavelengths were set at 360 nm and 450 nm, respectively, and the fluorescence of microtubule-bound DAPI was monitored as a function of time at 37°C. Fluorescence signal at time 0 for each well was subtracted from each of the subsequent fluorescence readings. Each compound was assayed in triplicate,
Tubulin competitive binding assay:
Competition assay was adapted from Giraudel et al, 1 98:
MTP (3 μΜ, final concentration) in PME buffer was mixed at G-4°C with compounds and tritiated competitor ([3H] colchicine (76.5 Ci.mmol"1, NEN) or [3H vinblastine (9.6 Ci.mmol-l, Amersham Biosciences) in a final volume of 200
Following 30 minutes incubation at 30°C, mixtures were deposited onto 50 ί of presedimented DEAE Sephadex A25 (to adsorb tubulin) in PME buffer. All subsequent steps were carried out at 0-4 CC. Samples were incubated for 10 min with continuous shaking to ensure quantitative binding of tubulin to the gel. Following centrifugation (2350 g, 4 min), supernatants were discarded and the pellets containing the bound molecule- tubulin complexes were washed four times with 1 niL volumes of PME buffer. Pellets were incubated for 10 min with 500 μΐ, of ethanol to solubilize the tubulin-bound tritiated competitor and 400 Ε aliquots of the ethanol solutions were transferred to 5 mL of Ultima Gold (Perkm-Elmer) scintillant for determination of radioactivity.
HUVEC tubulogenesis assay:
For this assay, ISO μΐ, of a mix of 85% Matrigel™ (Becton Dickinson) and 15%
EGM-2 medium (Cambrex) was allowed to polymerize at 37°C for 30 minutes in 48- multiwell plates. 3.105 HUVEC cells were seeded per well. Treatment with molecules (0.1, 1 and 10 μΜ) started right after cell attachment. Tubule formation was observed by phase- contrast microscopy at 24 hours.
RESULTS:
5-Azaindole compounds of formula (I) as reversible microtubule polymerization inhibitors:
The assay used to screen the chemical library was based on the substrate properties of the tubulin modifying enzymes involved in the tubulin tyrosination cycle. In this cycle the C-
terminal tyrosine of the tubulin cc-subunii is removed by a cafbox peptidase and re-introduced by tubulin tyrosine ligase (TTL). Because of the substrate properties of these enzymes, dynamic microtubules, sensitive to depolymerizing drugs, are composed of tyrosinated tubulin whereas non-dynamic, stabilized microtubules are composed of detyrosinated tubulin. Thus depolymerization or stabilization of the microtubule network can be easily distinguished by double-immunofluorescence staining using antibodies specific for tyrosinated and detyrosinated tubulin. This assay was used to screen a library of 6,560 compounds at 25 μ concentration. 158 compounds belonging to several distinct structural families and able to lower the signal down to at least 75% in the tyrosinated tubulin channel as compared with DMSO-treated cells were selected. The normal Hoechst signal observed with these compounds is an indirect estimation of the integrity of the cell monolayer. These results indicated that these hits were potential microtubule depolymerizing agents.
Table 1: Flow chart of the automated screening of the library and the subsequent analysis of active compounds
Category Parameter Description
Assay Type of assay Multiparametric ceil (HeLa)~based assay
Primary measurement IrrrniunoQuorescence detection, using a microplate reader, of detyrosinated and tyrosinated microtubules. Detection of nuclei density was performed with Hoechst staining
Key reagents HeLa cells, polyclonal antibody specific of detyrosinated tubulin, monoclonal antibody specific of tyrosinated tubulin
Assay protocol See Methods (Screening part)
Additional comments Importance of the settings of the microplate washer, to ensure accurate and homogenous cell washing, without rojuring the cell monolayer
Library Library size 6,560 molecules
Library composition Small molecules from chemical synthesis
Source Institut Curie-CNRS library (UMR 176), Orsay, France, which is part of the French "Chirniotheque Nationale
Additional comments Compounds arrayed in 96-welI plates as single compounds in DMSO (80 compounds per plate)
HTS process Format 96- ell plates, flat, black, opaque bottoms and walls
(Greiner)
Concentration tested 25 micromolar, 0.5% D SO
Plate controls Paelitaxei, Colchicine and DMSO were used as controls.
They were placed in each microplate, on the outer columns, alternating their locations. Additionally, a whole control plate was also daily performed.
Reagent/compound dispensing Fully automated platform, including 8-channel and 96- system channel dispensers
Detection instrument and FLUOstar OPTIMA microplate reader (BUG software Labtechnologies) and dedicated software
Correction factors Linear regression based on plate controls averages to reduce the impact of plate effects
Normalization Raw data converted into percentage of tyrosinated tubulin contents, based on plate controls averages
Posi-HTS analysis Hit criteria Tyrosinated tubulin content percentage < 75% and
Hoechst-stained DNA content > 90%
Hit rate 2.4%
Additional controls * Microscopic visualization
Elimination of compounds showing instability or excessive chemical reactivity and compounds with structure closely related to known microtubule targeting agents
Confirmation of hit purity LC-MS, MR, elementary analysis
Among the potential microtubule depolymerizing agents, the two potent 5-azaindole compounds of formula (I), CMOl and CM02, were more particularly studied as their scaffolds were drug-like, simple and their synthesis could give an easy access to numerous derivatives. Their effect on cellular microtubules was confirmed by immunofluorescence on HeLa cells fixed after permeabilization with OPT buffer. Whereas DMSO-treated cells exhibited a normal filamentous microtubule array, CM01/CM02 -treated cells were devoid of microtubules similarly to colchi cine-treated cells (Figure 1A). The changes of tubulin polymerization status were also checked by performing sequential extraction of soluble and insoluble pools of cellular tubulin. This enables the separation of unpoiymerized or depolymerized tubulin from microtubules. Decreasing concentrations (from 25 to 1 μΜ) of CMOl (Figure IB) and CM02 (Figure 1C) were tested and, whatever the concentration tested, a shift towards the unpoiymerized tubulin pool, similar to the effect elicited by colchicines, was observed, in depth the effects of CMOl and CM02 on microtubule dynamic
instability parameters, using tirae-Iapse fluorescence microscopy on GFP-EB3 transfected cells (Honore ei al.„ 2011) were analyzed and compared with those of colchicine. The concentrations assayed were detennined after a preliminary immunofluorescence analysis of the compounds effect on the microtubule network. The concentrations chosen were in a range that induces a detectable but not total depolymerization of the microtubule network. As does colchicine, CMOl and CM02 reduced the microtubule growth rate, increased time spent in pause and strongly reduced the microtubule growth length as indicated by the dose-dependent increase of the distance-based catastrophe frequency (Table 2). Table 2: Comparison of alteration of microtubule dynamic instability parameters induced by colchicine with that of CMOl and CMOl
Colchicine Colchicine
Parameters DMSO
Θ.05 μΜ 0.1 μΜ
% time spent growing 77.69 73.44 64.99
% time spent in pause 22.31 26.56 35.01
Growing rate (μπι/η η ± SE) 17.04 ± 0.22 15.32 ± 0.37*** 14.66 ± 0.28***
Catastrophe frequency { xva~l ± SE) 0.21 ± 0.01 0.33 ± 0.04** 0.40 ± 0.04***
Catastrophe frequency (miii1 ± SE) 2.83 ± 0.08 3.56 ± 0.29* 3.71 ± 0.35*
CMOl CMOl CM02 CM02
Parameters
0.05 μΜ 0.1 μΜ 0.05 μΜ 0.1 μΜ
% time spent growing 59.70 49.86 55.7? 42.64
% time spent in pause 40.30 50.14 44.23 57.36
Growing rate (μιη/min ± SE) 14.04 ± 0.36*** 13.18 * 0.30*** 13.35 ± 0.38*** 12.43 ± 0.31***
Catastrophe frequency (μπι"1 ± SE) 0.34 ± 0.03*** 0.53 ± 0,04*** 0.39 ± 0.03*** 0.78 ± 0.08***
Catastrophe frequency (rain 1 ± SE) 2.68 ± 0.33 3.28 ± 0.18* 2.89 ± 0.20 3.87 ± 0.29**
*p < 0.05; **ρ < 0.01, ***p < 0.001 significantly different from control values (DMSO) using a Student's t test
These results clearly show that CMOl and CM02 have a strong effect on microtubule dynamics.
The reversible microtubule depolymerizing effect induced by CMOl and CM02 was also tested (Figure 2) by replacing medium containing compounds by standard culture medium. Imraunostainmg of a-tubulin revealed that retrieval of compounds restored normal
microtubule array. These results demonstrate that CMOl and CM02 are celi-perraeable reversible microtubule polymerization iiihibitors.
5-Azaindole compounds of formula (I) are tubulin binders and compete with colchicines:
To test whether tubulin is a target of azaindole derivatives, in vitro microtubule polymerization assays were performed using either MTP or pure tubulin (Figures 3 and 4). In both cases, CMOl and CM02 inhibited tubulin polymerization in a dose-dependent manner. To determine compounds binding site on tubulin, effect of CMG1 and CM02 on tubulin binding of [3H] colchicine and [3H] vinblastine were investigated (Figure 5). CMOl and CM02 selectively inhibited colchicine but not vinblastine binding on tubulin. These results indicate that tubulin is a target of azaindole derivatives and mat azaindole derivatives bind to the colchicine-binding site but not to the vinca-alkaloids site.
Structure- Activity Relationships (SAR) analysis:
To explore the chemical properties conferring inhibitory potency to azaindole derivatives, several analogs of this family of compounds were selected and tested (Table 3),
Table 3: In vitro and cellular tubulin polymerization inhibitory activities of compounds of formula (I) wherein Ar is a phenyl ring
Substitaents at position
Tubulin assembly TjT-TubuUn signal
Compound
El R2 R3 Z (%) (%)
CMOl C¾ H oc¾ 0.0 0.0
CMQ2 c¾ H OCH3 oc¾ 0.0 0.0
CM03 Bn H OCH3 CH(CH3) Π.5 27.6
CM04 Bn H oc¾ O^CH^ 3.8 30.9
CMOS C¾ H OCH3 C(OH)C¾ 0.9 10.0
CMOS CH3 H H CH{C¾) 66.7 101.3
CM07 CH3 CI OCH3 CH(CH3> 9.6 0.0
CMOS C¾ H H C{OH)Ph 100.2 82.6
These assays were first conducted on in vitro tubulin assembly. The effects of the compounds were compared at a 25 μΜ concentration. The requirements of the inter-aromatic group Z were first investigated, The inhibitory potencies of the compounds were the same when an ethane (CMOl), an ethylene (CM02) or a hydroxyethyl (CMOS) was present in this position. This result indicates that the nature of the group Z is not a stringent determinant. Position Ri can also be substituted by either a small group (methyl, CMOl and CM02) or by a larger one (benzyl, CM03 and CM04) without loss in inhibitory potency. This indicates some tolerance to bulky substituents at position R5, Substitution of hydrogen by a chlorine group at position R2 (CM07) did not alter the inhibitory potency of the compound. The presence of an alkoxy group such as a methoxy group at position R3 was highly required for the compound to be active as illustrated by the results obtained with CM06 and CM08. The in vitro SAR correlated with cellular effect on microtubule network upon treatment with 5-azaindole compounds of formula (I) was also investigated, in this aim, cells grown on rmcroplates were incubated with the different compounds, fixed and processed for immunofluorescence. The quantification was done using the microplate reader, in the same way as for the primary screening. A good correlation was observed, which supports that tubulin is indeed the cellular target of azaindole derivatives, responsible for the observed phenotype.
Effect on cellular microtubules:
The effect on cellular microtubules of the 5~azaindole derivatives of formula (I) CM02 and CM10 was compared to that of indole derivatives CM11, CM12 and CM13 representative of the prior art WO 01/82909 A2.
HeLa cells grown for 72 hours on glass coverslips were incubated with compounds at indicated concentrations for 2 hours. They were then processed with the immunofluorescence procedure for microscopy analysis described above (Table 4).
Table 4: Immunofluorescence microscopy observations
The effect of the 5-azaindole derivatives of formula (I) CM02 and CM 10 on cellular microtubules was confirmed by immunofluorescence on HeLa cells fixed after pertneabilization with OPT buffer, whereas the indole derivatives CMll, CM12 and CM13 representative of the prior art WO 01/82909 A2 were proven to be completely inactive.
5-Azaindole compounds of formula (I) inhibit ceil proliferation of diverse cancer cell lines by promoting G2 M cell cycle arrest;
Viability of carcinoma cell lines from several organs (cervix, kidney, lung and breast) in response to CMOl and CM02 treatment was investigated using MTT assays (Table 5),
Table 5: Effects of 5-azaindole compounds of formula (I) on the viability of different cell lines
GI50 (50% of growth inhibition) were in the sub- or 3ow-raicromoIar range regardless the tissue origins, p53 or K-ras status of the cells. To determine the mode of action of the antiproliferative activity exhibited by azaindole derivatives, the distribution of CM01/CM02- treated cells in the cell cycle using flow cytometry was analyzed. Following 16 hours of exposure of the compounds at 1 μΜ or 25 μΜ, cells accumulated in G2/M phases (> 89%)
when compared to vehicle-treated cells (23%, Figure 6). Taken together, these experiments show that 5-azamdole compounds of formula (I) are potent cytostatic compounds, which block the cell cycle at G2/M phase.
5-AzaindoIe compounds of formula (I) overcome drug resistant (MDR) cell pheitotype:
The effect of CMOl and CM02 on cell proliferation of drug-sensitive sensitive cell- lines and of their drug-resistant counterparts that over-express the glycoprotein P or multidrug transporters such as ABCG2 and MRP] that confer cell resistance to multiple drugs (Marker et al, 1985) was compared (Table 5). CMOl and CM02 toxicity was found to be the same, with GI50 in the micromolar range, for the drug-sensitive human cell lines, and for their multidrug- resistant counterparts, indicating that it is not substrate of the glycoprotein V or of ABCG2 and MRPl transporters. This contrasts with the active efflux, at nanomolar concentrations, of colchicine and taxanes (pachtaxel and docetaxel) by Pglycoprotein, and of vinca alkaloids (vincristine and vinblastine) by both P -glycoprotein and MRPl (Dumontet et al, 1996; Fojo et al. , 2007; Szakacs et al, 2006).
5-Azaindoles compounds of formula (I) exhibit antiangiogenic effect;
Numerous compounds, such as combretastatins, which bind to the tubulin colcbicine- binding site, exhibit antiangiogenic effect. To investigate the putative antiangiogenic potency of azaindoles derivatives, CMOl and CM02 were tested in two different in vitro angiogenesis assays. The effect of the compounds on capillary-like tube formation on Matrigel was first investigated. It was found that both compounds were able to inhibit capillary tubes morphogenesis (Figure 7). A more integrated assay, i,e. 3 -dimensional cultures of HMEC- GFP cell spheroids in a collagen gel was used to anal ze the effects of increasing doses of the compounds on FGF2-stimulated endothelial cell sprouting. Although the compounds show no detectable toxicity on spheroids themselves (Figure 8A), they induced a dose dependent decrease of the mean length of total endothelial sprouts (Figure 8B). In both assays, CM02 showed a stronger effect than CMOl. These data indicate that 5-azaindoles compounds of formula (I) are potent antiangiogenic compounds.
5-Azaindoles compounds of formula (I) exhibit a»ti-tumorai effect on an in vivo model of invasive breast cancer :
Breast cancer cells (MDA-MB-231 expressing GFP) xenografted on the chicken chorioallantoid membrane were used to assess both toxicity and efficiency of CMOl and CM02 molecules. Tumors treated with these compounds were significantly smaller (P < 0.05; Figure 9A and 9B). Furthermore, upon treatment, chicken embryos did not display
significant increased mortality indicating that, in this model, these compounds are well tolerated at doses sufficient to induce antitumoral effect. The expression of GFP by the highly invasive MDA-MB-231 cells allowed an accurate detection, using fluorescence microscopy, of the dissemination of tumor cells in this model, as indicated by the number of nodules counted in the lower CAM (Figure 9C) in DMSO-treated embryos. The nodule number was greatly reduced in CMOl and CM02 treated embryos, indicating that azaindoles derivatives affect invasion mechanisms.
Bibliographic references:
Akhmanova A, Hoogenraad CC (2005). Microtubule plus-end-tracking proteins: mechanisms and functions. Curr Opin Cell Biol 17(1): 47-54.
Andrieux., A., P. Sa!in, A. Schweitzer, M. Begou, B. Pachoud, P. Bran, S. Gory-Faure, P. Kujala, M.F. Suaud-Chagny, G. Hofie, and D. Job. 2006. Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia. Biol Psychiatry. 60:1224- 30.
Andrieux, A., P.A. Salin, M. Vernet, P. Kujala, J. Baratier, S. Gory-Faure, C, Bosc, H. Pointu, D. Proietto, A. Schweitzer, E. Denarier, J, lumpennan, and D. Job. 2002. The suppression of brain cold-stable microtubules in mice induces synaptic defects associated with neuroleptic- sensitive behavioral disorders. Genes Dev. 16:2350-64.
Arora S, Wang XI, Keenan SM} Andaya C, Zhang Q, Peng Y, et al (2009). Novel microtubule polymerization inhibitor with potent antiproliferative and antitumor activity. Cancer- Res 69(5): 1910-1915. Begou, M.s J. Voile, J.B. Bertrand, P. Brun, D. Job, A. Schweitzer, M. Saoud, T. D'Amato, A. Andrieux, and M.F. Suaud-Chagny. 2008. The stop null mice model for schizophrenia displays [corrected] cognitive and social deficits partly alleviated by neuroleptics.
Neuroscience. 157:29-39, Bonne D5 Heusele C, Simon C, Pantaloni D (1985), 4',6-Diamid o-2~phenylindole, a fluorescent probe for tubulin and microtubules. J Biol Chem 260(5): 2819-2825.
Cailigaris D, Verdier-Pinard P, Devred F, Villard C, Braguer D, Lafitte D (2010) Microtubule targeting agents: from biophysics to proteomics. Cell Mol Life Sci 67(7): 1089-1104.
Castillo, A., H.C. Morse, 3rd, V.L. Godfrey, R. Naeem, and MJ. Justice. 2007.
Overexpression of Eg5 causes genomic instability and tumor formation in mice. Cancer Res. 67:10138-47. Coquelle FM, Vitre B, Arnal I (2009). Structural basis of EB1 effects on microtubule dynamics. Biochem Soc Trans 37(Pt 5): 997-1001,
De Rycker M, Rigoreau L, Dowding S, Parker PJ (2009). A high-content, cell -based screen identifies micropolyin, a new inhibitor of microtubule dynamics. Chem Biol Drug Des 73(6): 599-610. Dermaut, B., S. Kumar-Singh, R. Raderaakers, J. Theuns, M. Cruts, and C. Van Broeckhoven, 2005. Tau is centra! in the genetic Alzheimer-frontotemporal dementia spectrum. Trends Genet. 21 :664-72.
Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, Sikic ΒΪ (1996). Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 56(5): 1091-1097.
Echal er A, Bettayeb iC, Ferandin Y, Lozach O, Clement M, Valette A, et al (2008). Meriolins (3-(pyrimic%i-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclm A/meriolin complex. J Med Chem 51(4): 737-751.
Escuin D, Kline ER, Giannakakou P (2005), Both microtubule-stabilizing and microtubule- destabilizing drugs inhibit hypoxia-inducible factor- i alpha accumulation and activity by disrupting microtubule function. Cancer Res 65(19): 9021-9028.
Fojo T; Menefee M (2007). Mechanisms of multidrug resistance: the potential role of microtubulestabilizing agents. Ann Oncol 18 Suppl 5: v3-8.
Garcia, M.L., and D.W. Cleveland. 2001. Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. Curr Opin Cell Biol. 13:41-8.
Gasparini G (2001). Metronomic scheduling: the future of chemotherapy? The lancet oncology 2(12): 733-740. Giannakakou, P., D. Sackett, and T. Fojo. 2000, Tubulin/microtubules; still a promising target for new chemotherapeutic agents. J Natl Cancer Inst. 92:182-3.
Gigant, B,, C. Wang, R.B, Ravelli, F. Roussi, M.O. Steinmetz, P.A. Curmi, A. Sobel, and M. Knossow. 2005. Structural basis for the regulation of tubulin by vinblastine. Nature. 435:519- 22.
Giraudel A, Lafanechere L, Ronjat M, Wehland J, Garel JR, Wilson L, et al. (1998). Separation of tubulin subunits under nondenaturing conditions. Biochemistry 37(24): 8724- 8734.
Marker WG, Sikic BI (1985). Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA, Cancer Res 45(9); 4091-4096.
Holmfeldt F, Sellin ME, Gullberg M (2009). Predominant regulators of tubulin monomer- polymer partitioning and their implication for cell polarization. Cell Mol Life Sci 66(20): 3263-3276.
Hong S, Kim J, Seo JH, Jung KH, Hong SS (2012). Design, synthesis, and evaluation of 3,5- disubstituted 7-azaindoles as trk inhibitors with anticancer and antiangiogenic activities. / Med Ckem 55(11): 5337-5349.
Honore S, Braguer D (2011). Investigating microtubule dynamic instability using microtubuie-targeting agents. Methods Mol Biol 777: 245-260. Honore S, Pasquier E, Braguer D (2005). Understanding microtubule dynamics for improved cancer therapy. Cell Mol Life Sci 62(24): 3039-3056.
Jackson, J.R., D.R. Patrick, M.M. Dars and P.S. Huang. 2007, Targeted anti-mitotic therapies: can we improve on tubulin agents'? Nat Rev Cancer. 7:107-17.
Jordan MA, Kamath K (2007). How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 7(8); 730-742.
Jordan, M.A., and L, Wilson. 2004. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 4:253-65.
Kasibhatla S, Baichwal V, Cai SX, Roth B, Skvortsova I, Skvortsov S, et al, (2007). MPC- 6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res 67(12): 5865-5871.
Kavallaris M (2010). Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10(3): 194-204.
Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, et al. (1997). Taxol- resistant epithelial ovarian tumors are associated with altered expression of specific beta- rubulin isotypes. J Clin Invest 100(5): 1282-1293.
Kops, G.J., B.A. Weaver, and D.W. Cleveland. 2005. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 5:773-85.
Lafanechere L (2008), Chemogenomics and cancer chemotherapy: cell-based assays to screen for small molecules that impair microtubule dynamics. Comb Chem High Throughput Screen 11(8): 617-623, Lafanechere L, Co rtay-Cahen C, Lawakami T, Jacrot M, Rudiger M, Wehland J, ei al. (1998). Suppression of tubulin tyrosine Hgase during tumor growth, J Cell Sci 111 (Pt 2); 171-181.
Lafanechere L, Job D (2000). The third tubulin pool. Neurochem Res 25(1): 11-18,
Margalit, DJNL, L. Romberg, R.B. Mets, A.M. Hebert, TJ. MitcMson, M.W. Kirschner, and D. RayChaudhuri. 2004, Targeting cell division: small-molecule inhibitors of FtsZ GTPase perturb cytokinetic ring assembly and induce bacterial lethality. Proc Natl Acad Sci USA. 101:11821-6.
Merchan JR, Jayaram DR} Supko JG, He X, Bubley GJ, Sukhatme VP (2005). Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangio genie effects: potentiation by Cox-2 inhibition, Int J Cancer 113(3): 490-498, Morrissette, N.S., and L.D. Sibley. 2002. Disruption of microtubules uncouples budding and nuclear division in Toxoplasma gondii. J Cell Set 1 15: 1017-25,
Nguyen CH, E. B, Lhoste JM (1986), Synthese des derives N-5 substitues des 5H-pyrido [4,3- b] benzo[fJ indoles, isomeres des 6H-pyrido [4,3-b] earbazoles (ellipticines). Can. J. Chem. 64(3): 454-551.
Nguyen TL, McGrath C, Hermone AR, Burnett JC, Zaharevitz DW, Day BW, ei al, (2005). A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach, J Med Chem 48(19); 6107-6116.
Nien CY, Chen YC, uo CC, Hsieh HP, Chang CY, Wu JS, et al. (2010). 5-Arnrno-2- aroylq inolines as highly potent tubulin polymerization inhibitors. J Med Chem 53(5): 2309- 2313. Niethammer, P., I, Kronja, S, Kandels-Lewis, S, Rybina, P. Bastiaens, and E, arsenti, 2007. Discrete states of a protein interaction network govern interphase and mitotic microtubule dynamics. PLoSBiol. 5:e29.
Paturle-Lafanechere L, Edde B, Denoulet P, Van Dorsselaer A, azarguil H, I Caer JP, et al. (1991), Characterization of a major brain tubulin variant which cannot be tyrosinated. Biochemistry 30(43): 10523-10528. Paturle-Lafanechere L, Manier M, Trigault N, Pirollet F, Mazarguil H, Job D (1994). Accumulation of delta 2-tubulin, a major tubulin variant that cannot be tyrosinated, in neuronal tissues and in stable microtubule assemblies. J Cell Sci 107 (Pt 6): 1529-1543.
Peris L, Thery M, Faure J, Saoudi Y, Lafanechere L, Chilton JK, et al. (2006). Tubulin tyrosination is a major factor affecting the recruitment of CAP-Gly proteins at microtubule plus ends. J Cell Biol 174(6): 839-849.
Pasquier E, Honore S, Pourroy B, Jordan MA, Lehmann M, Briand C, et al (2005). Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 65(6); 2433-2440.
Peris L, Thery M, Faure J, Saoudi Y, Lafanechere L, Chilton JK, et al (2006), Tubulin tyrosination is a major factor affecting the recruitment of CAP-Gly proteins at microtubule plus ends. J Cell Biol 174(6): 839-849.
Pourroy B, Honore S, Pasquier E, Bourgarel-Rey V, ruczynski A, Briand C, et al, (2006). Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells. Cancer Res 66(6): 3256-3263. Prise VE, Honess DJ, Stratford MR, Wilson J, Tozer GM (2002). The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4- phosphate, at clinically relevant doses. Int Oncol 21(4): 717-726.
Ruthel, G,, G.L. Demmin, G. allstrom, M.P. Javid, S.S. Badie, A.B. Will, T. Nelle, R.
Schokman, T.L. Nguyen, J.H. Carra, S, Bavari, and M J. Aman. 2005. Association of ebola virus matrix protein VP40 with microtubules. J Virol 79:4709-19.
Small JV5 averina I (2003). Microtubules meet substrate adhesions to arrange cell polarity. Curr Opin Cell Biol 15(1): 40-47.
Snyder, J.P., J.H. Nettles, B. Cornett, K.H. Downing, and E. Nogales. 2001. The binding conformation of Taxol in beta-tubulin; a model based on electron crystallographic density, Proc Natl Acad Sci U S A 98:5312-6.
Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5(3): 219-234,
Tozer GM, Kanthou C, Bagaley BC (2005). Disrupting tumour blood vessels. Nat Rev Cancer 5(6): 423-435.
Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, et al. (2001). Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 61(17): 6413-6422.
Vacca A, Ribatti D, Presta M> Mimschetti M, lurlaro M, Ria , et al (1999). Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93(9): 3064-3073.
Vassal E5 Barette C, Fonrose X, Dupont R, Sans-Soleilhac E, Lafanechere L (2006). Miniaturization and validation of a sensitive multiparameter cell-based assay for the concomitant detection of microtubuledestabilizing and microtubule-stabilizing agents. J Biomol Screen 11(4): 377-389.
Zhou, J., and P. Giannakakou. 2005. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents, 5:65-71.
Claims
1. Compounds of formula (I):
in which:
~ the ring Ar is a C4-Ci2 aryl or heteroaryl ring,
- ] - Hj optionally substituted Ct-C6 alkyl, benzyl, arylsulfonyl, heteroarylsuifonyl, alkyloxycaxbonyl or dialkylcarbamoyl groups,
- R2 represents H or a halogen atom, nitro, amino, Cj-Ce alkylamino or C2-C6 cycloamino groups,
- R3, Rj, ¾ and R7, identical or different, represent hydrogen or halogen atoms, hydroxyl, Ci-C6 alkyl, Cj-Q alkoxy, cyano, nitro, carboxylate, carboxyester, amino Cj-Cs alkylamino or C2-C<¾ cycloamino groups,
- 4 = a halogen atom, hydroxy!, Ci-C^ alkoxy, amino, d- , alkylamino, C2-C6 cycloamino, thiol or Cj-Ce alkylthio groups, and
- Z = C=CHR, CR'R" or C=0, wherein R = H or an optionally substituted CrC6 alkyl group, and R' and R", identical or different, represent hydrogen or halogen atoms, OH gro ps, Ci-C6 alkyl or alkoxy groups, C4-C12 aryl, heteroaryl, arylalkyl or heteroarylalkyl groups,
or their tautomeric, racemic, enantiomeric or polymorphic forms or pharmaceutically- acceptable salts, for their use as drugs.
2. Compounds of formula (I) for their use according to Claim 1, wherein the ring Ar is a phenyl or pyridine ring, and preferably a phenyl ring.
3. Compounds of formula (I) for their use according to Claim 1 or Claim 2, wherein Z = C=CHR or CR'R", wherein R = H or an optionally substituted C C6 alky] group, and R! and R", identical or different, represent hydrogen or halogen atoms, OH groups, Ci-C6 alkyl or alkoxy groups, C4-Q2 ary > heteroaryl, arylalkyl or heteroarylalkyl groups.
4. Compounds of formula (I) for their use according to Claim 1 to 3, wherein Z = C-CH2 or CR'R" wherein R' - H or OH and R" - Cj-C6 alkyl or phenyl groups.
5. Compounds of formula (I) for their use according to Claims 1 to 4, wherein Z ~ C=CH2, CH(C¾)? C(OH)CH3 or C(OH)C6H5.
6. Compounds of formula (I) for their use according to Claims 1 to 5, wherein Ri = CH3 or a benzyl group.
7. Compounds of formula (I) for their use according to Claims 1 to 6, wherein R2 -
H r CI.
8. Compounds of formula (Γ) for their use according to Claims 1 to 7, wherein R3, R5, R& and R7, identical or different, represent hydrogen atoms or CpQ alkoxy groups.
9. Compounds of formula (I) for their use according to Claims 1 to 7, wherein at least one of the R3, R$5 Re or R7 radical is a OCH3 group.
10. Compounds of formula (I) for their use according to Claim 9, wherein the ring Ar is a phenyl ring substituted by a OCH3 group in position 4.
11. Compounds of formula (I) for their use according to Claims 1 to 30, wherein R4 = a halogen atom or a Cj-Ce alkoxy group.
12, Compounds of formula (I) for their use according to Claims 1 to 11 , wherein R4 =
CI or a OCH group.
13. Compounds of formula (I) for their use according to Claims 1 to 12, responding to one of the following formula:
CMOS
or
14. Compounds of formula (I) for their use according to Claims 1 to 13, for the prevention and/or the treatment of diseases and or disorders chosen amongst cancers; angiogenesis related disorders; parasitic diseases; fungal diseases; autoimmune diseases; inflammatory diseases; warts such as warts caused by papilloma virus.
15. Compounds of formula (I) for their use according to Claims 1 to 13, for the prevention and/or treatment of cancers chosen amongst testicular cancer, ovarian cancer, lung cancer, breast cancer, Hodgkm's disease, acute lymphoid leukemia, neuroblastoma, melanoma, glioma, glioblastoma, sarcoma, colon cancer, pancreatic cancer.
16. Compounds of formula (1) for their use according to Claims 1 to 13, for the prevention and/or treatment of angiogenesis related disorders chosen amongst diabetic blindness, macular degeneration, rheumatoid arthritis, psoriasis.
17, Compounds of formula (I) for their use according to Claims 1 to 13, for the prevention and/or treatment of parasitic diseases involving apicomplexan parasites, parasites with flagellum or cilia, toxoplasmosis.
18. Compounds of formula (I) for their use according to Claims I to 13, for the prevention and/or treatment of autoimmune diseases chosen amongst multiple sclerosis, diabet c retinopathy.
19. Compounds of formula (Γ) for their use according to Claims 1 to 13, for the prevention and/or treatment of inflammatory diseases chosen amongst gout disease.
20. A pharmaceutical composition comprising at least one compound of formula (I) as defined according to Claims 1 to 13 together with at least one pharmaceutically-acceptable excipient or carrier, and with at least another active substance.
21. Use of at least one compound of formula (1) as defined according to Claims 1 to 13 as research, tool for the cell-cycle synchronization of microtubule drugs resistant cell lines.
22, Use of at least one compound of formula (I) according to Claims 1 to 13 as an herbicide and/or an algaecide.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2012/054385 WO2014033497A1 (en) | 2012-08-27 | 2012-08-27 | 5-azaindole compounds with anticancer and antiangiogenic activities |
IBPCT/IB2012/054385 | 2012-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014033597A1 true WO2014033597A1 (en) | 2014-03-06 |
Family
ID=47045064
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2012/054385 WO2014033497A1 (en) | 2012-08-27 | 2012-08-27 | 5-azaindole compounds with anticancer and antiangiogenic activities |
PCT/IB2013/056809 WO2014033597A1 (en) | 2012-08-27 | 2013-08-22 | 5-azaindole compounds with anticancer and antiangiogenic activities |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2012/054385 WO2014033497A1 (en) | 2012-08-27 | 2012-08-27 | 5-azaindole compounds with anticancer and antiangiogenic activities |
Country Status (1)
Country | Link |
---|---|
WO (2) | WO2014033497A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023101722A1 (en) * | 2020-12-03 | 2023-06-08 | Medecine Innovations Group Inc. | Novel aza-substituted psilocin analogs and methods of synthesizing the same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001082909A2 (en) | 2000-04-28 | 2001-11-08 | Baxter Healthcare Sa | 2-acyl indol derivatives and their use as anti-tumour agents |
-
2012
- 2012-08-27 WO PCT/IB2012/054385 patent/WO2014033497A1/en not_active Application Discontinuation
-
2013
- 2013-08-22 WO PCT/IB2013/056809 patent/WO2014033597A1/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001082909A2 (en) | 2000-04-28 | 2001-11-08 | Baxter Healthcare Sa | 2-acyl indol derivatives and their use as anti-tumour agents |
Non-Patent Citations (63)
Title |
---|
AKHMANOVA A; HOOGENRAAD CC: "Microtubule plus-end-tracking proteins: mechanisms and functions", CURR OPIN CELL BIOL, vol. 17, no. 1, 2005, pages 47 - 54 |
ANDRIEUX, A.; P. SALIN; A. SCHWEITZER; M. BEGOU; B. PACHOUD; P. BRUN; S. GORY-FAURE; P. KUJALA; M.F. SUAUD-CHAGNY; G. HOFLE: "Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia", BIOL PSYCHIATRY, vol. 60, 2006, pages 1224 - 30 |
ANDRIEUX, A.; P.A. SALIN; M. VEMET; P. KUJALA; J. BARATIER; S. GORY-FAURE; C. BOSC; H. POINTU; D. PROIETTO; A. SCHWEITZER: "The suppression of brain cold-stable microtubules in mice induces synaptic defects associated with neuroleptic- sensitive behavioral disorders", GENES DEV, vol. 16, 2002, pages 2350 - 64 |
ARORA S; WANG XI; KEENAN SM; ANDAYA C; ZHANG Q; PENG Y ET AL.: "Novel microtubule polymerization inhibitor with potent antiproliferative and antitumor activity", CANCER RES, vol. 69, no. 5, 2009, pages 1910 - 1915 |
BEGOU, M.; J. VOLLE; J.B. BERTRAND; P. BRUN; D. JOB; A. SCHWEITZER; M. SAOUD; T. D'AMATO; A. ANDRIEUX; M.F. SUAUD-CHAGNY: "The stop null mice model for schizophrenia displays [corrected] cognitive and social deficits partly alleviated by neuroleptics", NEUROSCIENCE, vol. 157, 2008, pages 29 - 39 |
BONNE D; HEUSELE C; SIMON C; PANTALONI D: "4',6-Diamidino-2-pbenylindole, a fluorescent probe for tubulin and microtubules", J BIOL CHEM, vol. 260, no. 5, 1985, pages 2819 - 2825 |
CALLIGARIS D; VERDIER-PINARD P; DEVRED F; VILLARD C; BRAGUER D; LAFITTE D: "Microtubule targeting agents: from biophysics to proteomics", CELL MOL LIFE SCI, vol. 67, no. 7, 2010, pages 1089 - 1104 |
CAN J. CHEM, vol. 64, 1986, pages 545 |
CASTILLO, A.; H.C. MORSE, 3RD; V.L. GODFREY; R. NAEEM; M,J. JUSTICE: "Overexpression of Eg5 causes genomic instability and tumor formation in mice", CANCER RES., vol. 67, 2007, pages 10138 - 47 |
CHI HUNG NGUYEN ET AL: "Synthèse de dérivés N-5 substitués des 5H-pyrido[4,3-b]benzo[f]indoles, isomères des 6H-pyrido[4,3-b]carbazoles (ellipticines)", CANADIAN JOURNAL OF CHEMISTRY, vol. 64, no. 3, 1986, pages 545 - 551, XP055044466, ISSN: 0008-4042, DOI: 10.1139/v86-087 * |
COQUELLE FM; VITRE B; AMAL 1: "Structural basis of EB1 effects on microtubule dynamics", BIOCHEM SOC TRANS, vol. 37, 2009, pages 997 - 1001 |
DE RYCKER M; RIGOREAU L; DOWDING S; PARKER PJ: "A high-content, cell-based screen identifies micropolyin, a new inhibitor of microtubule dynamics", CHEM BIOL DRUG DES, vol. 73, no. 6, 2009, pages 599 - 610 |
DERMAUT, B.; S. KUMAR-SINGH; R. RADEMAKERS; J. THEUNS; M. CRUTS; C. VAN BROECKHOVEN: "Tau is central in the genetic Alzheimer-frontotemporal dementia spectrum", TRENDS GENET., vol. 21, 2005, pages 664 - 72 |
DUMONTET C; DURAN GE; STEGER KA; BEKETIC-ORESKOVIC L; SIKIC BI: "Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol", CANCER RES, vol. 56, no. 5, 1996, pages 1091 - 1097 |
ECHALIER A; BETTAYEB K; FERANDIN Y; LOZACH 0; CLEMENT M; VALETTE A ET AL.: "Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex", J MED CHEM, vol. 51, no. 4, 2008, pages 737 - 751 |
ÉMILE BISAGNI ET AL: "Lithiation de furo- et pyrrolo[3,2-c]pyridines substituées sur leur position 4", TETRAHEDRON, vol. 39, no. 10, 1983, pages 1777 - 1781, XP026596528, ISSN: 0040-4020, [retrieved on 19830101], DOI: 10.1016/S0040-4020(01)88687-7 * |
ESCUIN D; KLINE ER; GIANNAKAKOU P: "Both microtubule-stabilizing and microtubule- destabilizing drugs inhibit hypoxia-inducible factor-lalpha accumulation and activity by disrupting microtubule function", CANCER RES, vol. 65, no. 19, 2005, pages 9021 - 9028 |
FOJO T; MENEFEE M: "Mechanisms of multidrug resistance: the potential role of microtubulestabilizing agents", ANN ONCOL, vol. 18, no. 5, 2007, pages V3 - 8 |
GARCIA, M.L.; D.W. CLEVELAND: "Going new places using an old MAP: tau, microtubules and human neurodegenerative disease", CURR OPIN CELL BIOL., vol. 13, 2001, pages 41 - 8 |
GASPARINI G: "Metronomic scheduling: the future of chemotherapy?", THE LANCET ONCOLOGY, vol. 2, no. 12, 2001, pages 733 - 740 |
GIANNAKAKOU, P.; D. SACKETT; T. FOJO: "Tubulin/microtubules: still a promising target for new chemotherapeutic agents", JNATL CANCER INST., vol. 92, 2000, pages 182 - 3 |
GIGANT, B.; C. WANG; R.B. RAVELLI; F. ROUSSI; M.O. STEINMETZ; P.A. CURMI; A. SOBEL; M. KNOSSOW: "Structural basis for the regulation of tubulin by vinblastine", NATURE, vol. 435, 2005, pages 519 - 22 |
GIRAUDEL A; LAFANECHERE L; RONJAT M; WEHLAND J; GAREL JR; WILSON L ET AL.: "Separation of tubulin subunits under nondenaturing conditions", BIOCHEMISTRY, vol. 37, no. 24, 1998, pages 8724 - 8734 |
HARKER WG; SIKIC BL: "Multidrag (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA", CANCER RES, vol. 45, no. 9, 1985, pages 4091 - 4096 |
HOLMFELDT P; SELLIN ME; GULLBERG M: "Predominant regulators of tubulin monomer- polymer partitioning and their implication for cell polarization", CELL MOL LIFE SCI, vol. 66, no. 20, 2009, pages 3263 - 3276 |
HONG S; KIM J; SEO JH; JUNG KH; HONG SS: "Design, synthesis, and evaluation of 3,5- disubstituted 7-azaindoles as trk inhibitors with anticancer and antiangiogenic activities", J MED CHEM, vol. 55, no. 11, 2012, pages 5337 - 5349 |
HONORE S; BRAGUER D: "Investigating microtubule dynamic instability using microtubule-targeting agents", METHODS MOL BIOL, vol. 777, 2011, pages 245 - 260 |
HONORE S; PASQUIER E; BRAGUER D: "Understanding microtubule dynamics for improved cancer therapy", CELL MOL LIFE SCI, vol. 62, no. 24, 2005, pages 3039 - 3056 |
JACKSON, J.R.; DR. PATRICK; M.M. DAR; P.S. HUANG: "Targeted anti-mitotic therapies: can we improve on tubulin agents?", NAT REV CANCER, vol. 7, 2007, pages 107 - 17 |
JORDAN MA; KAMATH K: "How do microtubule-targeted drugs work?", AN OVERVIEW, CURR CANCER DRUG TARGETS, vol. 7, no. 8, 2007, pages 730 - 742 |
JORDAN, M.A.; L. WILSON: "Microtubules as a target for anticancer drugs", NAT REV CANCER, vol. 4, 2004, pages 253 - 65 |
KASIBHATLA S; BAICHWAL V; CAI SX; ROTH B; SKVORTSOVA 1; SKVORTSOV S ET AL.: "MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps", CANCER RES, vol. 67, no. 12, 2007, pages 5865 - 5871 |
KAVALLARIS M: "Microtubules and resistance to tubulin-binding agents", NAT REV CANCER, vol. 10, no. 3, 2010, pages 194 - 204 |
KAVALLARIS M; KUO DY; BURKHART CA; REGL DL; NORRIS MD; HABER M ET AL.: "Taxol- resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes", J CLIN INVEST, vol. 100, no. 5, 1997, pages 1282 - 1293 |
KOPS, G.J.; B.A. WEAVER; D.W. CLEVELAND: "On the road to cancer: aneuploidy and the mitotic checkpoint", NAT REV CANCER, vol. 5, 2005, pages 773 - 85 |
LAFANECHERE L: "Chemogenomics and cancer chemotherapy: cell-based assays to screen for small molecules that impair microtubule dynamics", COMB CHEM HIGH THROUGHPUT SCREEN, vol. 11, no. 8, 2008, pages 617 - 623 |
LAFANECHERE L; COURTAY-CAHEN C; KAWAKAMI T; JACROT M; RUDIGER M; WEHLAND J ET AL.: "Suppression of tubulin tyrosine ligase during tumor growth", J CELL SCI, vol. 111, 1998, pages 171 - 181 |
LAFANECHERE L; JOB D: "The third tubulin pool", NEUROCHEM RES, vol. 25, no. 1, 2000, pages 11 - 18 |
MARGALIT, D.N.; L. ROMBERG; R.B. METS; A.M. HEBERT; T.J. MITCHISON; M.W. KIRSCHNER; D. RAYCHAUDHURI: "Targeting cell division: small-molecule inhibitors ofFtsZ GTPase perturb cytokinetic ring assembly and induce bacterial lethality", PROC NATL ACAD SCI U S A., vol. 101, 2004, pages 11821 - 6 |
MERCHAN JR; JAYARAM DR; SUPKO JG; HE X; BUBLEY GJ; SUKHATME VP: "Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition", INT J CANCER, vol. 113, no. 3, 2005, pages 490 - 498 |
MORRISSETTE, N.S.; L.D. SIBLEY: "Disruption of microtubules uncouples budding and nuclear division in Toxoplasma gondii", J CELL SCI., vol. 115, 2002, pages 1017 - 25 |
NGUYEN CH, E. B; LHOSTE JM: "Synthese des derives N-5 substitues des 5H-pyrido [4,3-b] benzo[f] indoles, isomeres des 6H-pyrido [4,3-b] carbazoles (ellipticines", CAN. J CHEM., vol. 64, no. 3, 1986, pages 454 - 551 |
NGUYEN TL; MCGRATH C; HERMONE AR; BURNETT JC; ZAHAREVITZ DW; DAY BW ET AL.: "A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach", JMED CHEM, vol. 48, no. 19, 2005, pages 6107 - 6116 |
NIEN CY; CHEN YC; KUO CC; HSIEH HP; CHANG CY; WU JS ET AL.: "5-Amino-2- aroylquinolines as highly potent tubulin polymerization inhibitors", J MED CHEM, vol. 53, no. 5, 2010, pages 2309 - 2313 |
NIETHAMMER, P.; I. KRONJA; S, KANDELS-LEWIS; S. RYBINA; P. BASTIAENS; E. KARSENTI: "Discrete states of a protein interaction network govern interphase and mitotic microtubule dynamics", PLOS BIOL., vol. 5, 2007, pages E29 |
PASQUIER E; HONORE S; POURROY B; JORDAN MA; LEHMANN M; BRIAND C ET AL.: "Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells", CANCER RES, vol. 65, no. 6, 2005, pages 2433 - 2440 |
PATURLE-LAFANECHERE L; EDDE B; DENOULET P; VAN DORSSELAER A; MAZARGUIL H; LE CAER JP ET AL.: "Characterization of a major brain tubulin variant which cannot be tyrosinated", BIOCHEMISTRY, vol. 30, no. 43, 1991, pages 10523 - 10528 |
PATURLE-LAFANECHERE L; MANIER M; TRIGAULT N; PIROLLET F; MAZARGUIL H; JOB D: "Accumulation of delta 2-tubulin, a major tubulin variant that cannot be tyrosinated, in neuronal tissues and in stable microtubule assemblies", J CELL SCI, vol. 107, 1994, pages 1529 - 1543 |
PERIS L; THERY M; FAURE J; SAOUDI Y; LAFANECHERE L; CHILTON JK ET AL.: "Tubulin tyrosination is a major factor affecting the recruitment of CAP-Gly proteins at microtubule plus ends", J CELL BIOL, vol. 174, no. 6, 2006, pages 839 - 849 |
POURROY B; HONORE S; PASQUIER E; BOURGAREL-REY V; KRUCZYNSKI A; BRIAND C ET AL.: "Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells", CANCER RES, vol. 66, no. 6, 2006, pages 3256 - 3263 |
PRISE VE; HONESS DJ; STRATFORD MR; WILSON J; TOZER GM: "The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses", INT J ONCOL, vol. 21, no. 4, 2002, pages 717 - 726 |
RENAUD PRUDENT ET AL: "Azaindole derivatives are inhibitors of microtubule dynamics, with anti-cancer and anti-angiogenic activities", BRITISH JOURNAL OF PHARMACOLOGY, vol. 168, no. 3, 16 February 2013 (2013-02-16), pages 673 - 685, XP055090025, ISSN: 0007-1188, DOI: 10.1111/j.1476-5381.2012.02230.x * |
RUTHEL, G.; G.L. DEMMIN; G. KALLSTROM; M.P. JAVID; S.S. BADIE; A.B. WILL; T. NELLE; R. SCHOKMAN; T.L. NGUYEN; J.H. CARRA: "Association ofebola virus matrix protein VP40 with microtubules.", J VIROL., vol. 79, 2005, pages 4709 - 19 |
S. MAHBOOBI, J. MED. CHEM., vol. 49, 2006, pages 3101 - 3115 |
SIAVOSH MAHBOOBI ET AL: "Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents", JOURNAL OF MEDICINAL CHEMISTRY, vol. 44, no. 26, 2001, pages 4535 - 4553, XP002210359, ISSN: 0022-2623, DOI: 10.1021/JM010940+ * |
SMALL JV; KAVERINA I: "Microtubules meet substrate adhesions to arrange cell polarity", CURR OPIN CELL BIOL, vol. 15, no. 1, 2003, pages 40 - 47 |
SNYDER, J.P.; J.H. NETTLES; B. COMETT; K.H. DOWNING; E. NOGALES: "The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density", PROC NATL A CAD SCI USA, vol. 98, 2001, pages 5312 - 6 |
SZAKACS G; PATERSON JK; LUDWIG JA; BOOTH-GENTHE C; GOTTESMAN MM: "Targeting multidrug resistance in cancer", NAT REV DRUG DISCOV, vol. 5, no. 3, 2006, pages 219 - 234 |
TOZER GM; KANTHOU C; BAGULEY BC: "Disrupting tumour blood vessels", NAT REV CANCER, vol. 5, no. 6, 2005, pages 423 - 435 |
TOZER GM; PRISE VE; WILSON J; CEMAZAR M; SHAN S; DEWHIRST MW ET AL.: "Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability", CANCER RES, vol. 61, no. 17, 2001, pages 6413 - 6422 |
VACCA A; RIBATTI D; PRESTA M; MINISCHETTI M; IURLARO M; RIA R: "Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma", BLOOD, vol. 93, no. 9, 1999, pages 3064 - 3073 |
VASSAL E; BARETTE C; FONROSE X; DUPONT R; SANS-SOLEILHAC E; LAFANECHERE L: "Miniaturization and validation of a sensitive multiparametric cell-based assay for the concomitant detection of microtubuledestabilizing and microtubule-stabilizing agents", J BIOMOL SCREEN, vol. 11, no. 4, 2006, pages 377 - 389 |
ZHOU, J.; P. GIANNAKAKOU: "Targeting microtubules for cancer chemotherapy", CURR MED CHEM ANTICANCER AGENTS., vol. 5, 2005, pages 65 - 71 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023101722A1 (en) * | 2020-12-03 | 2023-06-08 | Medecine Innovations Group Inc. | Novel aza-substituted psilocin analogs and methods of synthesizing the same |
US11939292B1 (en) | 2020-12-03 | 2024-03-26 | Mydecine Innovations Group Inc. | Aza-substituted psilocin analogs and methods of synthesizing the same |
US11952342B2 (en) | 2020-12-03 | 2024-04-09 | Mydecine Innovations Group Inc. | Aza-substituted psilocin analogs and methods of synthesizing the same |
Also Published As
Publication number | Publication date |
---|---|
WO2014033497A1 (en) | 2014-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Prudent et al. | Azaindole derivatives are inhibitors of microtubule dynamics, with anti‐cancer and anti‐angiogenic activities | |
Wang et al. | Synthesis, biological evaluation and molecular docking of benzimidazole grafted benzsulfamide-containing pyrazole ring derivatives as novel tubulin polymerization inhibitors | |
Su et al. | Design, synthesis and biological evaluation of new quinoline derivatives as potential antitumor agents | |
Liu et al. | Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1, 2, 4-triazolone moiety as c-Met kinase inhibitors | |
JP2018528246A (en) | TEAD transcription factor self palmitoylation inhibitor | |
US8604048B2 (en) | Pyridocarbazole type compounds and applications thereof | |
PT2663564E (en) | Imidazo[4,5-c]quinolin-2-one compound and its use as pi3 kinase / mtor dual inhibitor | |
BR112021002633A2 (en) | compound, pharmaceutical composition, method of treating a subject in need thereof, compound for use, use of a compound, kit, method of treating a subject who has multiple myeloma, method of identifying whether a subject who has multiple myeloma is a candidate for treatment with a compound, method of predicting the outcome of treatment in a subject having multiple myeloma, and method comprising administering a therapeutically effective amount of a compound | |
US8119640B2 (en) | Hedgehog pathway antagonists methods of use | |
JP2022504541A (en) | Small MDM2 Protein Degrader | |
Shaik et al. | Design and synthesis of 1, 2, 3-triazolo linked benzo [d] imidazo [2, 1-b] thiazole conjugates as tubulin polymerization inhibitors | |
Gomez-Monterrey et al. | Heat shock protein 90 inhibitors as therapeutic agents | |
AU2015374155A1 (en) | Novel calcium modulators | |
WO2016141296A1 (en) | Tricyclic kinase inhibitors of melk and methods of use | |
CA3214155A1 (en) | Methods for inhibiting ras | |
Porcù et al. | Novel 9′-substituted-noscapines: synthesis with Suzuki cross-coupling, structure elucidation and biological evaluation | |
JP2018510876A (en) | Fused bicyclic compounds for disease treatment | |
US20200024235A1 (en) | Crystal form and salt form of and preparation method for tyrosine kinase inhibitor | |
Henderson et al. | UA62784, a novel inhibitor of centromere protein E kinesin-like protein | |
EP3013331B1 (en) | Multitarget hedgehog pathway inhibitors and their use for the treatment of certain hedgehog (hh)-dependent tumors | |
Wang et al. | Design, synthesis and anticancer activity of 5-aryl-4-(4-arylpiperazine-1-carbonyl)-1, 2, 3-thiadiazoles as microtubule-destabilizing agents | |
WO2016040951A1 (en) | Compounds and methods for inhibition of hedgehog signaling and phosphodiesterase | |
WO2014033597A1 (en) | 5-azaindole compounds with anticancer and antiangiogenic activities | |
Indorato et al. | STLC-resistant cell lines as tools to classify chemically divergent Eg5 targeting agents according to their mode of action and target specificity | |
WO2022171163A1 (en) | Methods of modulating androgen receptor condensates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13785610 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WA | Withdrawal of international application |